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Abstract
MicroRNAs (miRNAs) are stable, small non-coding RNAs that modulate many downstream target genes. Recently, circulating
miRNAs have been detected in various body fluids and within exosomes, prompting their evaluation as candidate
biomarkers of diseases, especially cancer. Kaposi’s sarcoma (KS) is the most common AIDS-associated cancer and remains
prevalent despite Highly Active Anti-Retroviral Therapy (HAART). KS is caused by KS-associated herpesvirus (KSHV), a
gamma herpesvirus also associated with Primary Effusion Lymphoma (PEL). We sought to determine the host and viral
circulating miRNAs in plasma, pleural fluid or serum from patients with the KSHV-associated malignancies KS and PEL and
from two mouse models of KS. Both KSHV-encoded miRNAs and host miRNAs, including members of the miR-17–92 cluster,
were detectable within patient exosomes and circulating miRNA profiles from KSHV mouse models. Further characterization
revealed a subset of miRNAs that seemed to be preferentially incorporated into exosomes. Gene ontology analysis of
signature exosomal miRNA targets revealed several signaling pathways that are known to be important in KSHV
pathogenesis. Functional analysis of endothelial cells exposed to patient-derived exosomes demonstrated enhanced cell
migration and IL-6 secretion. This suggests that exosomes derived from KSHV-associated malignancies are functional and
contain a distinct subset of miRNAs. These could represent candidate biomarkers of disease and may contribute to the
paracrine phenotypes that are a characteristic of KS.
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Introduction
MicroRNAs (miRNAs) are small, non-coding RNAs that are
capable of fine-tuning gene expression through translational
repression and/or mRNA degradation. In the past, miRNAs have
emerged as important regulators in nearly every cellular process,
but perhaps the largest biological consequence of miRNA
dysregulation is in cancer [1,2,3,4,5,6]. The relationship between
intra-tumor miRNA signatures and cancer progression has been
well established, leading to the discovery of specific miRNAs or
miRNA clusters that modulate gene expression in cancer [7,8,9].
We and others have shown that miRNA signatures can classify
tumors into distinct classes and are predictive of disease outcome
[3,4,6,10,11]. In our prior study, we found that the host miRNA
profile differed depending on the degree of transformation among
cells, even though all samples were infected by the same virus and
thus expressed similar levels of viral miRNAs [6]. This suggests
that host miRNA profiles impart information about viral infection
above that provided by detecting the presence of the infectious
agent.
MiRNA regulation is complex in malignancies associated with
viral infection such as herpesvirus-associated cancers [2,6,12,13].
Viral infection can trigger changes in the miRNA profile through
the expression of viral genes that modulate the host miRNA
repertoire. Some viruses such as Kaposi’s sarcoma-associated
herpesvirus (KSHV) and Epstein-Barr Virus (EBV) in addition
encode their own miRNAs, which fine-tune host gene expression
to promote latent viral persistence, immune evasion, and tumor
progression [8,9,14,15,16,17]. These viral miRNAs are often
expressed within the tumor and can reveal important information
regarding viral latency and disease progression [18]. Furthermore,
recent studies have highlighted important functions of the viral
miRNAs in regulation of the viral life cycle, immune evasion
and angiogenesis through validated mRNA targets [7,14,19,
20,21,22,23]. In KSHV-associated cancers, the KSHV miRNAs
can account for as much as 20% of all mature miRNA species
within a cell and are highly conserved among isolates (Figure S1
and [12,14,17]).
KSHV is the etiological agent of Kaposi’s sarcoma (KS), the
most common AIDS-defining cancer worldwide [24]. KSHV is
also associated with the B cell lymphoma Primary Effusion
Lymphoma (PEL) and with the plasmablastic variant of Multi-
centric Castleman’s Disease (MCD). Despite the availability of
Highly Active Anti-Retroviral Therapy (HAART), KS continues
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to occur in the US and worldwide. Treatment of KS remains a
challenge and stable, minimally invasive biomarkers for diagnosis
are lacking [25,26]. Therefore, the discovery of plasma miRNA
biomarkers for KSHV-associated malignancies could improve
diagnostics through early detection and could influence treatment
through non-invasive monitoring of tumor responses. MiRNA
biomarkers can be sampled from blood, saliva, or other bodily
fluids, offering a feasible diagnostic test even in resource-poor
regions such as the ‘‘KS belt’’ in sub-Saharan Africa [24,27]. Viral
microRNAs are the most attractive candidate biomarker because
of their specificity for KSHV. However, a combination of viral
microRNAs with cellular microRNA biomarkers is even more
useful, as it may help differentiate among stages of KS progression
or response to therapy and as it can identify cellular microRNAs
that are common among KS and other cancers. We previously
determined the cellular and viral miRNA profile in KS tumor
biopsies as well as in PEL and found that the expression of viral
miRNAs varies with disease state [3,4,6]. In addition to the viral
miRNAs, key cellular miRNAs are involved in KSHV transfor-
mation and KS progression [8,9,28,29].
The detection of circulating miRNAs in plasma, serum and
other bodily fluids suggests their utility as minimally invasive
biomarkers for cancer diagnostics [11,30,31,32,33,34]. These
circulating miRNAs are unusually stable (i) due to their packaging
in microvesicles or exosomes, (ii) due to their RNA folding and size
and/or (iii) due to their presence in Ago-containing ribonucleic
acid:protein (RNP) complexes [32,34,35,36]. At this point it is
unclear which of these mechanisms is the most efficient. Evidence
suggests that all three mechanisms contribute to diagnostic utility
by increasing miRNA stability. There are a variety of vesicles that
are secreted from cells, each with slightly varying content and
surface marker composition. Microvesicles can range in size from
30 nm–1000 nm and each follow different pathways of biogenesis
(reviewed in [37,38,39]). Recent studies have additionally shown
that microvesicles from tumor cells may have altered morphology,
size and surface markers, including the expression of tumor
antigens compared to microvesicles that are released from non-
tumor cells [40,41,42,43]. MiRNAs have been detected in
microvesicles, exosomes and/or nanovesicles. This study refers
to these vesicles collectively as exosomes based on common surface
marker expression and morphological characteristics.
Transfer of exosomes and their contents from tumor cells to
surrounding, uninfected cells may be an important form of cellular
communication and has been demonstrated in cell culture models,
for instance in EBV-associated cancers [44,45]. Additionally,
exosomes may provide a means of paracrine signaling from virally
infected cells to adjacent, non-permissive cells [46]. This study
attempts to bridge the gap between clinical samples and cell
culture models. To do so we compared the detailed, circulating
miRNome of KS in clinical human samples and in KS mouse
models [47,48,49]. This confirms the presence of circulating KS
and KSHV-specific miRNAs in vivo in the context of KSHV
infection. Multiple KSHV miRNAs and members of the miR-17-
92 cluster of cellular miRNAs were detected within patient
exosomes. These circulating miRNA signatures may serve as a
new mechanism of paracrine signaling for mediating KSHV
pathogenesis and may represent a reservoir for novel biomarkers.
Results
Clinical samples and mouse models of KSHV-associated
malignancies
To date, most studies on viral exosomes have used tissue culture
models of infection. To expand on these studies, we utilized a
series of clinical samples and two novel robust mouse models of
KSHV pathogenesis [47,48,49]. The sample groups and number
of samples included in each group are outlined in Table S1.
Briefly, human plasma from healthy, KSHV-negative controls or
from AIDS patients with either KS or a non-KS malignancy was
used to isolate exosomes. The HIV viral load and CD4+ T cell
counts were similar in both KS and non-KS malignancy groups
(data not shown). KS tumor biopsies and primary PEL pleural
fluid were also included and served as positive controls for the
presence of KSHV compared to control human plasma. We also
used two mouse models previously characterized in our lab
[47,48,49]: the 801 latency locus transgenic mouse model which
expresses all viral miRNAs in B cells [50]; and a xenograft model
using TIVE L1 tumor cells, which maintain KSHV [48]. These
cells are xenografted into SCID mice, which results in robust and
reproducible tumor formation [48]. H&E staining revealed similar
phenotypes of KS and our TIVE xenograft mouse model while
both of these differed from the staining observed in PEL (Figure
S2).
The KSHV-TIVE model [48] represents another instance of
extended yet incomplete KSHV lytic transcription, as recently
demonstrated in KSHV-infected lymphatic endothelial cell
cultures under puromycin selection [51] and previously in
KSHV-infected mouse endothelial cells [52]. Similarly, a KSHV
cell line model of transformed rat mesenchymal precursors yields
some lytic gene expression but with minimal amounts of virions
produced [53]. The KSHV-TIVE endothelial cell model main-
tains KSHV in the absence of selection and like other long-term
KSHV-infected endothelial cell cultures they remain tightly latent.
Neither sodium butyrate nor exogenously provided RTA/Orf50
are able to induce infectious virus production (R.Renne, personal
communication) or complete, genome-wide lytic transcription in
TIVE L1 cells [48]. Subcutaneous implantation into mice can
activate many viral genes, although these represent only approx-
imately half of the genes turned on during lytic reactivation in PEL
Author Summary
Circulating microRNAs (miRNAs), such as those found in
exosomes, have emerged as diagnostic tools and hold
promise as minimally invasive, stable biomarkers. Transfer
of tumor-derived exosomal miRNAs to surrounding cells
may be an important form of cellular communication.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the
etiological agent of Kaposi’s sarcoma (KS), the most
common AIDS-defining cancer worldwide. Here, we survey
systemically circulating miRNAs and reveal potential
biomarkers for KS and Primary Effusion Lymphoma (PEL).
This expands previous tissue culture studies by profiling
clinical samples and by using two new mouse models of
KSHV tumorigenesis. Profiling of circulating miRNAs
revealed that oncogenic and viral miRNAs were present
in exosomes from KS patient plasma, pleural effusions and
mouse models of KS. Analysis of human oncogenic
miRNAs, including the well-known miR-17-92 cluster,
revealed that several miRNAs were preferentially incorpo-
rated into exosomes in our KS mouse model. Gene
ontology analysis of upregulated miRNAs showed that
the majority of pathways affected were known targets of
KSHV signaling pathways. Transfer of these oncogenic
exosomes to immortalized hTERT-HUVEC cells enhanced
cell migration and IL-6 secretion. These circulating miRNAs
and KS derived exosomes may therefore be part of the
paracrine signaling mechanism that mediates KSHV path-
ogenesis.
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cells and are insufficient to produce infectious virions. A similar,
abortive lytic expression profile has been observed in KSHV-
infected human TIVE-L1 cells [48] as well as in KSHV-infected
mouse and rat endothelial cells [52,53]. This incomplete
transcription program is incompatible with virion production
and in the case of KSHV-infected LEC has been termed a novel
latency program [51]. For this reason, we refer to the TIVE
xenograft mouse model as a latent KSHV model due to the lack of
virions produced.
Exosome purification and analysis of miRNAs
Exosomes and circulating miRNAs were purified as shown in
Figure 1A and detailed in methods. Following purification, total
RNA was isolated from each sample group and used for Taqman-
based qPCR profiling of the cellular miRNA repertoire (754
human miRNAs) as described [3,4,54]. Agilent RNA analysis
showed that exosomes expressed small RNAs but lacked both 18S
and 28S ribosomal RNA (Figure S3). Figure 1 shows the distribution
of miRNAs in different sample subsets (Figure 1B–E). Each boxplot
shows the expression levels for the different sample groups. The
expression of individual microRNAs are denoted by solid circles. As
demonstrated in Figure 1B, the majority of miRNAs present in
control human plasma (KSHV2) in the supernatant fraction are
susceptible to RNase, representing free, circulating miRNAs. These
miRNAs are likely not encapsulated in Ago-RNP complexes nor
microvesicles [35]. The exceptions were miRNAs miR-16, miR-195
and miR-197, which could be detected despite RNase treatment.
This RNase resistance of these particular miRNAs is consistent with
prior observations [35]. Levels of the C. elegans cel-mir-39 spike-in
were abolished ,16,000-fold after RNase treatment and were
decreased when incubated with pleural fluid prior to RNA isolation
(Figure S4). This verifies the activity of our RNase treatment and
confirms that pleural fluid, like other body fluids, has some intrinsic
RNase activity [33,34,35]. Therefore, the majority of RNAs that are
stable in plasma and pleural fluid are likely RNase-resistant and
protected within exosomes.
In samples enriched for exosomes derived from either control
human plasma or mouse serum, we were able to readily detect
both human and mouse miRNAs (Figure 1C). Figure 1D denotes
the relative expression levels of miRNAs in cells, exosomes and the
free, circulating fractions of control human plasma. As expected,
exosomal and other circulating miRNAs are detectable but are
present at lower levels compared with intracellular miRNAs.
MiRNAs are readily detected in all sample types tested including
tumor biopsies and exosomes from control plasma or serum and
malignant effusions such as pleural fluid (Figure 1E), though the
miRNA yield was highest in tumor tissue. Although we used
human plasma and serum from mice in the majority of
experiments, we also performed miRNA profiling with control
mouse plasma. Importantly, we did not observe significant
Figure 1. Exosome purification and analysis of miRNAs in sample subsets. Exosomes were purified and miRNAs isolated from exosome
samples were analyzed for expression in various subsets. (A) Schematic for profiling of circulating miRNAs from plasma, serum and pleural fluid
samples. (B–E) Box plots show the distribution of relative levels (CT) for 12 miRNAs for various conditions (mir-106b, mir-150, mir-16, mir-195, mir-197,
mir-205, mir-23a, mir-30c, mir-425-5p, mir-548a, mir-92a, U6 snRNA). We selected those miRNAs, as they were highly expressed and as being
representative of the different patterns we see across the experimental controls. Two independent experiments were performed and both replicates
are shown. The line represents the median expression of microRNAs for a given sample group while individual microRNAs are denoted by closed
circles (n = 24). In some cases, the median of the group is equal to 50 and the line is along the x axis due to .50% of miRNAs with a CT = 50. MiRNA
expression following RNase treatment of control human plasma supernatants (B), comparison of human and mouse exosomal miRNA expression in
control human plasma and mouse serum (C), differential expression in purified subsets from control human plasma (D) and tissue-specific expression
(E) are shown. Asterisks denote previously detected plasma miRs [35].
doi:10.1371/journal.ppat.1003484.g001
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differences in the levels of miRNAs found in plasma versus serum
in this study. The comparison of this small subset of miRNAs
across the different variables shown in Figure 1B–E did not afford
us the statistical power to identify differences among individual
miRNAs expressed in these samples. However, these data establish
the framework for further analysis and confirms qPCR as a
reliable platform for the profiling of miRNAs in a diverse group of
clinical samples [54,55]. Furthermore, we validate the presence of
exosomal miRNAs in cell-free patient plasma and mouse serum.
Validation of exosomes and expression of exosomal
markers
Isolation of exosomes using the Exoquick method has previously
been validated to yield similar electron microscopy (EM) structures
and miRNA array populations as other techniques [56]. None-
theless, we sought to confirm the presence of exosomes in our
patient samples using two independent isolation techniques.
Enriched exosomes from the Exoquick protocol revealed similar
structures via electron microscopy compared to exosomes enriched
by differential ultracentrifugation (Figure 2A). However, while
Exoquick samples did contain exosomes (determined by size and
morphological characteristics), they yielded images with high
background by electron microscopy due to the crowding agent
present in the ExoQuick solution. This background was not due to
contaminating cellular debris, as high-speed centrifugation and
elimination of cellular debris using a sucrose cushion failed to
eliminate background in the EM images (Figure S5). By
comparison, differential ultracentrifugation yielded exosomes of
similar size and morphology with minimal background (Figure 2A).
Patient pleural fluid and BCBL1 cell supernatant yielded exosomes
that appeared similar by EM. We therefore pursued the Exoquick
method for further study, as these samples required much less
sample input, a key benefit when working with clinical samples
and mouse models.
To further establish the purity of our exosomes, we performed
Western blots for previously established exosomal markers
including the tetraspanin CD9, Hsp90 alpha/beta and flotillin
[57,58]. We first analyzed the expression of flotillin, which is
enriched in exosomes [58,59,60]. Flotillin was expressed in all
human and mouse exosome samples (Figure 2B,C) but was not
present in the supernatant fractions containing freely circulating
miRNAs (Figure 2D, S). Hsp90 alpha and beta, which are also
highly enriched in exosomes, were detected in PEL cells and
pleural fluid-derived exosomes but, as expected, were absent in the
supernatant fraction (Figure 2E–G). Finally, we assessed the
expression of the tetraspanin CD9, another exosomal marker. The
KS exosomal subgroup (KS-E) expressed detectable levels of CD9
whereas the supernatant fraction (S) did not express the exosome
marker (Figure 2H). As a negative control for exosomes, we used
the exosome-depleted supernatant fraction from BJAB cells (-).
The mouse exosome samples isolated from serum of control and
transgenic (Tg) mice also showed robust expression of the CD9
exosome marker, indicating that these samples are enriched for
exosomes (Figure 2H). The increased expression observed in the
mouse samples most likely reflects the ratio of input used to the
total fluid volume present in human and mouse. A mouse has a
total blood volume of 1.5 mls of which we use 250 ul (,17%)
whereas human blood volume is approximately ,5 L of which we
used 250 ul (0.005%). We also tested the presence of exosomal
markers in samples purified by ultracentrifugation and received
similar results, validating the use of the Exoquick method for our
study (Figure S6). Furthermore, the ExoQuick method yields more
exosomes than other methods tested and uses approximately 100-
fold less starting material.
KSHV miRNAs are detectable in the exosome-enriched
fraction
Increased expression of KSHV miRNAs correlates with disease
state and tumor progression in endothelial cells [3,6]. EBV viral
miRNAs have been detected in exosomes isolated from cultured
lymphoma cell lines, NPC patients and xenografted mice [44,45],
but thus far it has not been shown that KSHV miRNAs are also
loaded into exosomes. To address this question, we examined
patient-derived exosomes for the presence of KSHV-encoded
miRNAs. Figure 2I shows the qPCR products separated by size on
a Caliper nanofluidics platform. Exosomes derived from serum of
three independent KSHV-positive TIVE L1 xenograft tumor mice
and PEL fluid contained KSHV miR-K2 (Figure 2I). Total RNA
from KSHV-positive latently-infected BCP-1 PEL cells were used
as a positive control. KSHV miRs K12-4-5p, K12-4-3p, K12-5,
K12-6-5p, K12-10a and K12-11 were also detected in pleural fluid
and xenograft tumor mice (data not shown). KSHV miRNAs were
undetectable in the KSHV-negative BJAB cell line (Figure 2I).
This shows that systemically circulating exosomes contain
appreciable levels of mature KSHV miRNAs and therefore
exosomes containing KSHV miRNAs can travel from the
subcutaneous tumor graft into the bloodstream and are stable
enough to circulate systemically. Since we harvested the blood at
day 10–15 after tumor cell injection, this result is likely to reflect
steady-state levels of exosomal miRNAs. Notably, the L1 TIVE
xenograft model does not generate infectious virus [48]. Hence,
exosome encapsulated KSHV miRNAs show promise as a highly
sensitive marker for latent KSHV tumor cells.
In order to study exosome-associated viral miRNAs in more
detail, we used the BCBL1 PEL cell line to assess KSHV miRNA
expression. We found that 14 out of 14 KSHV microRNAs tested
were expressed at detectable levels in exosomes from latent
BCBL1 cells (Figure S7). Methods for purifying virions and
exosomes can lead to co-precipitating of both exosomes and
virions, therefore making it difficult to physically separate them for
analysis. To distinguish the source of these viral miRNAs as
exosomal or virion-associated, we purified exosomes using three
different techniques. In addition to using the ExoQuick method of
purification, we also utilized differential ultracentrifugation and a
new bead affinity purification technique that positively selects for
CD63+ exosomes, an exosomal marker not present on KSHV
virions. Expression of KSHV microRNAs was then assessed
following enrichment of exosomes using either method (Figure 3,
Figure S7). In addition, we passed the samples through a 0.2 mm
filter prior to exosome isolation but after the removal of cellular
debris. Although KSHV virions are approximately 180 nm in size,
they tend to aggregate, a phenomenon well-recognized in earlier
studies studying infectivity of cell-free virus [61,62,63]. This
aggregation of virions makes it difficult to clear even a 0.2 mm
filter. This was experimentally confirmed by filtering concentrated
KSHV stocks, which resulted in a decrease in titer of approx-
imately 4 logs (data not shown). Exosomes, however, which range
in size from 30–100 nm, can easily pass through a 0.2 mm filter, as
is evident from EM imaging of filtered patient-derived exosomes
(Figure 2A). Consistent with this, the expression levels of KSHV
miRNAs were only slightly affected by filtering (Figure 3A, Figure
S7). By contrast, filtering of exosome samples resulted in a
dramatic decrease in viral load (Figure 3B). We observed similar
expression patterns of viral miRNAs in exosomes isolated and
filtered following both ExoQuick and ultracentrifugation methods.
This was confirmed by Caliper gel electrophoresis, which showed
the presence of KSHV miRNA products in both the exosome and
filtered exosome fractions (Figure S7). A lower shifted band
corresponding to primer dimers was detected in the no template
Exosome MiRNA Signature of KS
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control reactions. Note also that the Caliper images represent non-
quantitative accumulation of product after 55 cycles, whereas
quantification was based on the exponential phase of the PCR
reaction.
Using the CD63+ exosome isolation method, we consistently
observed expression of KSHV miRNAs regardless of filtration
(Figure 3A). The levels of viral miRNAs were not significantly
different in exosome preparations from latent or lytically induced
PEL cells (Figure 3A). If these miRNAs were predominantly
present within virions, we would expect a robust increase in viral
miRNA levels concomitantly with increased virion production
following reactivation as we observed for KSHV load (Figure 3B).
Furthermore, RNase treatment of samples slightly decreased viral
miRNA levels in the CD632 supernatant but did not affect
KSHV miRNA expression in CD63+ fractions, suggesting that
these miRNAs are primarily protected within exosomes (data not
shown). Analysis of exosomes isolated by CD63 affinity capture
confirmed the presence of CD9, another well established exosomal
marker (Figure 3F). CD9 levels were unaffected by filtering
samples and RNase treatment (Figure 3F). Taken together, this
demonstrates that the KSHV miRNAs are predominantly
contained within exosomes released from latently-infected tumor
cells.
Analysis of viral load in exosome-enriched samples
Having determined that viral miRNAs were present in
exosomes, we next sought to analyze the distribution of KSHV
DNA among our samples and biochemical fractions. There are
two mechanisms that lead to KSHV viral DNA being detectable in
body fluids: (i) virions [64], (ii) tumor cell-released free viral DNA,
as has been demonstrated for EBV [65,66,67,68]. To eliminate the
contribution of cell-free viral DNA, we treated all samples with
DNase prior to DNA isolation. We evaluated BCBL1-derived
exosomes purified using different techniques for the presence of
KSHV DNA (Figure 3B, C). Exosome-enriched samples were
passed through a 0.2 mm filter, which led to a drastic decrease in
KSHV load using both purified virus stock and exosomes
(Figure 3B, data not shown). Although the viral load increased
Figure 2. Characterization of patient- and mouse model-
derived exosomes. (A) EM images of exosomes prepared from
patient and tissue culture samples using Exoquick and ultracentrifuga-
tion (UC) methods. PF1, pleural fluid patient 1; PF2, pleural fluid patient
2; BCBL1 – PEL cell line. Scalebar is shown below images. (B–H)
Abbreviations are as follows: CHP – Control, KSHV(2) Human Plasma,
AMT – patients with non-KS AIDS malignancies, KS – Kaposi’s Sarcoma
patients, PF – Primary PEL Pleural Fluid, Ctrl – Control Mouse Serum, Tg
– KSHV Latency Locus Transgenic Mouse Model, Xeno – TIVE-KSHV
Xenograft Mouse Model, (2) KSHV-negative BJAB cell line. The
exosomal markers flotillin-2 (B,C), Hsp90 alpha (E,G), Hsp90 beta (F)
and CD9 (H) were analyzed by Western blot in human and mouse
exosomes (abbreviated E) isolated using the Exoquick method.
Exosome-depleted supernatants (abbreviated S) were also analyzed
for the presence of Flotillin (B,D) and Hsp90 alpha (E,G). CD9 was
detected in mouse exosome samples and exosomes from KS patients
(KS), confirming our method of exosome isolation (H). As expected, the
exosomal marker was absent in the supernatant fraction and in our
negative control BJAB exosome-depleted supernatant fraction. Flotillin
was present in exosomes derived from control (Ctrl), transgenic (Tg) and
xenograft (Xeno) mouse models but was not present in the supernatant
fraction. Hsp90 alpha and beta were expressed in PEL cells (VG1, a
KSHV+ PEL cell line) and pleural fluid-derived exosomes (PF) but not in
the supernatant. (I) KSHV miR-K2 expression was determined by qPCR
and products were run on the Caliper LabChip GX. BCP1-KSHV (+) PEL
cell line, Exo – RNA from exosome fraction, Cells – RNA from cell pellet.
Exo1,2 and 3 denote three individual TIVE xenograft mice.
doi:10.1371/journal.ppat.1003484.g002
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following reactivation, filtering of exosomes from lytic BCBL1 cells
abolished viral load to approximately the limit of detection. DNase
treatment of samples, which effectively eliminated freely circulat-
ing tumor-associated DNA, further decreased KSHV load in
filtered fractions (data not shown).
We also compared the presence of viral DNA in exosome and
supernatant fractions of samples enriched by CD63 bead affinity
purification or differential centrifugation (Figure 3C). Viral DNA
was detected in the exosome-depleted supernatant fraction
(CD632) after bead affinity purification but was undetectable in
the CD63+ exosome fraction. Conversely, viral DNA was enriched
in the exosome pellet following differential ultracentrifugation, as
both virions and exosomes sediment at similar densities during
centrifugation. This establishes CD63-based affinity capture as an
efficient way to separate exosomes and virions. Since we detected
KSHV miRNAs, but not KSHV DNA in the CD63-affinity purified
exosomes, this suggests that the primary source of the viral miRNAs
we observe is exosomes rather than virions.
We also evaluated viral load in exosomes purified using the
ExoQuick method. The advantage of the ExoQuick method
compared to CD63 capture is greater efficiency (using only 250 ml
as input), which is essential when profiling large numbers of
Figure 3. Analysis of KSHV miRNA expression and viral DNA in exosome samples. Box plot representation of miR-K12-11 expression (A)
and KSHV load (B) in latent and lytic exosomes purified using the CD63+ Dynabeads method. Sample filtration is noted below each plot. MiRNA
expression is shown as fold above background and viral load data is shown as copy number of LANA DNA per reaction. (C) Box plot of viral load for
filtered samples purified using either CD63 (left panel) or differential ultracentrifugation (centri, right panel). Viral load is shown for both exosome
(exo) and supernatant (sn) fractions. Asterisks denote significance of p#0.05. (D, E) KSHV viral load from ExoQuick samples was determined by qPCR
(D) and products were run on the Caliper LabChip GX (E). (D) Sample groups are as follows: neg (control human and mouse samples negative for
KSHV), ntc (no template control), KS or PEL (KS patients and primary PEL fluid), pos (dilutions of oligonucleotide positive controls; high to low
concentrations) and tive (xenograft mouse models of KS). (E) Sample abbreviations are as follows: KS = plasma from KS, AMT = AIDS Malignancy, non-
KS, PF = pleural fluid, CHP = control human plasma, E = exosome fraction, S = exosome-depleted supernatant fraction. (F) Western blot for the
exosomal marker CD9. Samples were enriched for exosomes using CD63+ Dynabeads and were filtered prior to bead purification as noted. Resulting
CD63+ and CD632 fractions were treated with RNase as denoted and protein lysates were evaluated. As a positive control, a lysate of pleural fluid-
derived exosomes using the ExoQuick (EQ) method were assessed for CD9 expression.
doi:10.1371/journal.ppat.1003484.g003
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clinical samples. We found KSHV DNA in both exosomal and
free supernatant fractions of plasma and pleural fluid
(Figure 3D,E). The highest viral load was found in exosomes
derived from PEL pleural fluid. No viral DNA was detected in our
negative control samples or in exosomes purified from non-KS,
HIV+ patients (Figure 3D, 3E lanes CHP and AMT respectively).
Both ExoQuick and ultracentrifugation methods yielded KSHV
DNA in the KS patient plasma and PEL fluid exosome fraction
(Figure 3). Thus, neither differential centrifugation not ExoQuick
can with certainty be used to separate exosomes from virion
particles. However, CD63+ exosomes contain little KSHV DNA,
especially following filtering of exosome samples. This novel
method confirms that the majority of the signal detected in the
viral load assay was due to free DNA and KSHV virion DNA.
KSHV protein and virions are not detected in exosome-
enriched samples
To further address the possibility that virions may also be
present in our exosome fraction and may contribute to our results,
we looked for KSHV virions and viral proteins in our exosome-
enriched samples. We did not detect any virions by EM following
ExoQuick or ultracentrifugation isolation of exosomes (Figure 2A).
We analyzed more than 20 grids for the presence of virions in our
exosome-enriched samples. Quantitative analysis of exosome-
enriched pellets by differential centrifugation revealed 2,319
exosomes and no virions on three sample grids. The supernatant
fraction was also imaged by EM for the presence of exosomes and
only 13 exosomes were detected, validating ultracentrifugation as
an efficient method for exosome isolation. We also compared the
number of exosomes from latent and lytic BCBL1 cell superna-
tants by EM. Both latent and lytic samples had similar numbers of
exosomes detected on representative grids, averaging 135 and 126,
respectively (while the DNase resistant viral load differed by .10-
fold). This suggests that the presence of exosomes in our samples
may be static and independent of virus production.
Finally, we probed exosome-enriched samples for KSHV
structural proteins. KSHV K8.1 was readily detected in BCBL1
PEL cells following lytic reactivation (Figure S8). However, PF-
derived exosomes, which contained the highest viral load of our
samples, did not express K8.1. These data confirm that our
exosome-enriched samples do not contain appreciable levels of
KSHV virions (Figures S7, S8). Although KSHV protein and
DNA are not found in exosomes, we find systemically circulating
KSHV miRNAs in exosomes derived from patients, tissue culture
models and mouse models of KS (Figure 2I, Figures S7, S8). This
establishes exosome-associated viral miRNAs as new biomarkers
for KSHV-associated cancers. It also suggests that detecting viral
miRNAs may offer greater sensitivity of diagnosing viral infection
than viral load measurements.
miRNA profiling reveals distinct oncomiR and exosome
signatures
To obtain a more complete picture, we profiled the host miRNA
repertoire in each of our sample groups using both exosomal and
exosome-depleted supernatant preparations. The C. elegans cel-mir-
39 spike-in was used as an internal normalizing control. Unsuper-
vised clustering analysis revealed two distinct clusters, which are
shown as projected onto the first three principal components
(Figure 4A). Unsupervised clustering groups samples and the
different miRNAs based on similar expression levels. The result is
typically shown as a heatmap. Principal component analysis is used
to reduce the complexity of the data further without loss of statistical
power. It combines the multiple measurements of each sample (or
each miRNA) to such that the data can be represented in three
dimensions (the principal component axes). Individual analysis of
the human and mouse profiling samples (Figures 4B,C) illustrates
the more divergent clusters representing miRNAs elevated in tumor
versus control samples in the mouse model. We expected to see
more defined clusters in our mouse models since the xenografts
represent biological replicates with limited variability compared
with human clinical samples. The miRNA profile in the human
samples alone clearly separated samples into KSHV-associated and
control groups.
When we further narrowed the miRNAs to known oncomiRs
and tumor suppressor miRNAs, the classification improved
(Figure 4D). A list of these ,150 oncomirs and tumor suppressor
miRNAs is shown in Table S2. As a negative control for our
analysis we clustered an unrelated sample. We performed
unsupervised clustering of miRNAs in HEK293 cells following
infection with West Nile Virus (WNV) (Chugh and Dittmer,
unpublished data). This comparison yielded very different clusters
of miRNAs compared with the KSHV exosome data as noted by
further predicted target analysis (Table 1). This establishes a
unique oncomir signature of KS- and PEL-associated exosomes.
We further examined the expression of individual oncomirs and
tumor suppressor miRNAs in the mouse exosome subset by
heatmap analysis (Figure 4E). Oncomirs were defined as host
miRNAs readily studied for their role in tumorigenesis and related
cancer signaling pathways while tumor suppressor miRNAs have
been demonstrated to functionally inhibit these processes (Table
S2). We identified this subset of oncogenic miRNAs because (a) we
previously extensively validated these assays [3,4,55] and (b) they
represent miRNAs with experimentally verified expression and
function. The most distinct expression pattern was the apparent
separation between TIVE xenograft and control mouse serum
(Figure 4E, Panel i). The majority of oncomiRs in this cluster were
increased in exosomes from KS xenograft tumor models and were
only minimally or not detectable in the control mice (ctrl versus
xeno). We next compared miRNA expression profiles of control
and xenograft mice to our latency locus transgenic mouse model
(Figure 4E, Panel ii). In this novel model, only the KSHV latent
genes and miRNAs are expressed in B cells [50]. However, none
of the viral structural genes are present. We found that exosomes
derived from the transgenic model differed from that of control
mice and shared some oncogenic miRNA expression with the
xenograft mice. As this transgenic mouse model phenotype
represents B cell hyperplasia, these highly expressed miRNAs
may be reflective of change in the miRNome regulated by the
KSHV latency locus prior to tumor formation (Figure 4E).
We further compared the exosomal miRNA profile of
transgenic mice to that of PEL-associated exosomes from primary
pleural fluid (Figure 4E, panels iii, iv). This yielded similarities in
induced exosomal oncogenic miRNA expression between the 801
transgenic mouse model and PEL patient fluid (Panel iii, Cluster
1). Interestingly, we also identified a subset of microRNAs that was
solely induced in the KSHV latency locus transgenic mouse model
(Figure 4E, Panel iv, Cluster 2). Figure S9 further compares the
exosomal miRNA profile in an independent set of transgenic and
control mice and indicates elevated levels of oncogenic miRNA
expression in the transgenic mouse model.
Analysis of miRNA profiles in both Clusters 1 and 2 also
revealed a subset of oncogenic miRNAs that were exclusively
expressed in exosomes, suggesting that these miRNAs may be
preferentially incorporated from the tumor site into exosomes for
intercellular communication (Figure 4E, Panels iii,iv, Figure S10).
Taken together, we find that the most elevated oncomiR levels in
exosomes were observed in the TIVE xenograft tumor group, as
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these mice were bearing large, well-vascularized tumors, which
facilitates expression and release of miRNAs. This demonstrates
for the first time that exosomal miRNAs, including KSHV
miRNAs, can be detected in mouse models of KS.
Our human clinical samples of AIDS-KS recapitulated the trends
in oncogenic miRNA expression observed in our mouse models
(Figure 4F, Figure S11). Cluster 1 represents a subset of oncogenic
miRNAs that are most highly expressed in exosomes derived from
PEL pleural fluid (Figure 4F). Several miRNAs in this cluster were
also elevated in KS patient-derived exosomes. This pattern of
miRNA expression may reflect a signature of KSHV-associated
malignancies. A subset of miRNAs within this cluster could also
represent miRNAs overexpressed in KS and other cancers since we
observed oncogenic miRNA induction in other AIDS malignancies
as well as KS-associated exosomes (Figure 4F). Cluster 2 shows
another subset of miRNAs with elevated expression in exosomes
from KS or AIDS malignancy patients. This cluster also includes
several miRNAs that seem to be preferentially expressed within
exosomes compared to the supernatant fraction.
We noticed little difference in the miRNA profile from control
plasma exosomes versus RNase-treated control plasma exosomes,
indicating that exosomes are indeed resistant to RNase treatment
[35](Figure 4F, lanes CHP exo and RNase-CHP exo). We also
compared the miRNA profile in pleural fluid-derived exosomes
exposed to RNase to determine if they responded similarly to our
exosomes from control human plasma. Exosomes from PEL
patient pleural fluid exhibited higher levels of miRNA expression.
RNase treatment only slightly changed the miRNA profile, similar
to that observed in control exosomes (Figure S12). This
demonstrates that different patient samples respond similarly to
Figure 4. miRNA profiling reveals distinct oncomiR and exosome subsets. Profiling of miRNAs led to the discovery of distinct signatures for
oncomiRs and exosome subsets. Cluster separation of miRNA expression by principal component analysis (PCA) of (A) all miRNAs profiled, (B) human
samples, (C) mouse samples and (D) oncogenic miRNAs in human samples. MiRNAs were clustered by their levels of expression to reveal two distinct
clusters of expression patterns: one with generally high expression in KS and PEL samples (purple, cluster 1) and one with high expression in another
subset of samples specific to a control, malignancy or exosome-specific (shown in yellow, cluster 2). Each solid circle represents one microRNA and
lines are drawn from each point to the centroid or mean position of points in a given cluster. This centralized point allows for the largest difference
between clusters and minimizes the distance of points within a given cluster to the centroid. Heatmaps reflective of unsupervised clustering analysis
are shown for oncomirs in (E) mouse and (F) human samples. Enlarged heatmaps with microRNA labels are shown separately as Figures S10, S11. (E)
Oncomirs from mouse models are shown as a series of panels (i–iv). Panel i compares oncogenic miRNA expression between control mice and
individual TIVE xenograft mice. Profiling data from the transgenic mouse model encoding the KSHV latency locus is shown in Panel ii with control
mice and the average of the TIVE xenograft data. Panels iii and iv show two separate clusters of miRNA expression and compare control and
transgenic mice to the primary human PEL pleural fluid cases. Abbreviations of mouse samples are as follows: CMP – control mouse plasma, CMS –
control mouse serum, TIVE 1–3, individual TIVE xenograft mice, tg – 801 latency locus mouse model, PF – primary human PEL pleural fluid, exo –
exosomes, sup – exosome-depleted supernatants. (F) Oncomir expression in human samples is shown as two separate clusters of expression. For the
human oncomiR heatmap, sample lanes from left to right are: CHP sup pre-exo - control human plasma supernatant pre-ExoQuick, CHP E – control
human plasma exosomes, CHP S – control human plasma exosome-depleted supernatant, RNase CHP E – RNase-treated CHP exo, RNase CHP S –
RNase-treated CHP sup, AMT E – AIDS Malignancy, non-KS exo, AMT S – AIDS Malignancy, non-KS sup, KS E – Kaposi’s sarcoma exosomes, KS S –
Kaposi’s sarcoma exosome-depleted supernatant, PF E – pleural fluid exosomes, PF S – pleural fluid exosome-depleted supernatant. Red denotes high
expression, green denotes low expression and black is basal or intermediate expression.
doi:10.1371/journal.ppat.1003484.g004
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RNase treatment and further validates that the majority of our
signal was derived from exosome-contained miRNAs.
Since patient samples may display a high degree of genetic
variability and therefore miRNA signatures could differ, we sought
to address the issue of individual variance of patient miRNA
profiles using three PEL patients. Pleural fluid-derived exosomes
were independently isolated and the miRNA expression profile
was compared to that of control human exosomes. Many of the
‘‘PEL signature’’ miRNAs were expressed in all three patients,
suggesting that these could be used as novel biomarkers of PEL
present in pleural fluid (Figure S13). Another subset of miRNAs
was expressed in 2 out of 3 patients. Since PEL is a rare
malignancy, we obtained only three patients, each of varying
disease states. Different factors such as disease state, co-infection
with EBV or HIV status could contribute to absence of these
biomarkers in one of the patients. However, despite the inherent
genetic variability among patients, we could identify multiple
miRNAs that were expressed at high levels in all three PEL
patients compared to controls (Figure S13).
Analysis of oncomiRs, the miR-17-92 cluster miRNAs and
exosomal miRNA subsets
We further analyzed the expression of the oncomiR cluster in
the exosome sample subsets. For this analysis, we defined a relative
expression score based on the CT where a higher expression score
corresponds to a lower CT. Specifically, we calculate the
expression class by binning CTs such that a CT of 20–25
corresponds to an expression value of 3. MicroRNAs expressed
with CTs of 25–30 are assigned an expression value of 2.5. Scores
are assigned in 0.5 increments until CT of 45+ equals zero, or not
detected. In addition to patient-derived exosomes, we determined
the miRNA profile for KS biopsies and PBMCs derived from
control human plasma. The full profiling data is shown in Figure
S14. Figure 5A demonstrates that, as expected, KS biopsies (KS,
left) displayed the highest expression of oncomirs. By comparison,
a large number of oncomirs were undetectable (expression
score = 0) in biofluids. KS-associated exosomes also contained
oncomirs in moderate (expression score = 1) and some at very high
levels (expression score = 2). While oncomiRs are readily expressed
in both control and malignant samples, we found that the number
of highly expressed oncogenic miRNAs was lower in control
exosomes (Neg). Note that members of the miR-17–92 cluster are
denoted by blue dots and are highly expressed in KS biopsies and
KS-associated exosomes compared with controls (expression
score.1.5). The levels of oncogenic miRNAs were abolished in
exosome-depleted supernatant fractions treated with RNase
(Figure 5A). The exceptions were miRNAs including miR-16,
miR-195 and miR-197, which were previously shown to be
RNase-resistant (Figure 1B, [35]). This demonstrates that most
oncogenic miRNAs were present in exosomes. Oncomirs specif-
ically expressed in tumor samples at the highest expression level
included miR-106a, miR-17, miR-454, let-7e, miR-451, miR-886-
5p, miR-601 and miR-625 (expression score of $2, Figure 5A).
Note, that a high expression score is the result of both the
underlying high level of expression of the specific miRNA species
and the sensitivity of the particular qPCR assay.
One of the most well-studied oncogenic miRNA clusters is the
miR-17-92 cluster. The 6 mature miRNA species in this cluster
tend to be co-regulated [69] and we previously found this miR
cluster upregulated in KS [3,4]. Members of the paralog cluster
miR-106b/25 are also well-known for their role in tumorigenesis
and share target genes with the miR-17-92 cluster [70,71]. We
therefore investigated whether KS-associated exosomes contained
members of these two miRNA clusters. In our clinical and mouse
model samples, levels of the miR-17-92 and miR-106b/25 clusters
were induced in exosomes derived from KSHV-associated mouse
serum, primary human pleural fluid and KS biopsies compared
with control exosomes (Figure 5B, C). Since we did not observe a
similar enrichment of all tumor-associated miRNAs within the
exosomes, these miR-17-92 members are likely to be preferentially
incorporated into exosomes. Members of these oncogenic clusters
were slightly elevated in exosomes from KS patient plasma,
although this was not statistically significant (Figure 5B). However,
exosomes derived from pleural fluid expressed much higher levels
of the miR-17-92 and miR-106b-25 cluster members, with the
exception of miR-25 and miR-92a (Figure 5B). The increased
expression of oncogenic miRNAs within PF-derived exosomes
may be because of direct contact of the pleural fluid to PEL cells,
suggesting that malignant effusions may be a very effective source
for obtaining exosomes (Figure 5B). Induction of the miR-17-92
cluster member miRNAs was most pronounced when we
compared exosomes derived from the xenograft mouse model to
control mouse exosomes (Figure 5C, p#.000059). Therefore, we
find that exosome-associated oncomirs are uniquely upregulated in
samples from KS tumor-bearing animals and primary PEL
patients. Interestingly, even the B cell hyperplasia latency locus
transgenic mouse model showed increased levels of these miRNAs
in systemically circulating exosomes (Figure 5C, p#0.05).
Several miRNAs seemed to be preferentially incorporated into
exosomes (Figure 4E,F). Therefore, we analyzed these in detail. As
shown in Figure 5D, miRNAs miR-19a, miR-21, miR-27a, miR-130
and miR-146a were enriched within exosomes and virtually
undetectable as free, circulating miRNAs in the supernatant. Their
Table 1. GO Pathway analysis of induced oncomiR targetsa.
KSHV WNV Migrationb
Pathway No.c P valued No. P value
Pathways in Cancer* 18 8.35 E-05 18 0.09 X
Adipocytokine signaling 8 2.08E-04 NA NA
Pancreatic Cancer* 8 3.26E-04 NA NA
MAPK signaling* 15 3.39E-04 17 0.04 X
Adherens junction* 7 2.80E-03 NA NA X
TGF-beta signaling* 7 5.15E-03 NA NA X
Fc gamma R phagocytosis 7 7.89E-03 NA NA
Focal adhesion* 9 3.15E-02 NA NA X
TLR signaling* 6 3.83E-02 NA NA
Wnt signaling* 7 5.97E-02 12 0.02 X
Colorectal cancer 5 6.91E-02 7 0.09
NSCLCe 4 7.73E-02 NA NA
AMLf 4 9.13E-02 NA NA
aThe oncomiRs that were upregulated in the KSHV-associated sample groups
were input into a microRNA target prediction database (MAMI). The predicted
targets (determined with highest stringency) were used as input for the GO
pathway database DAVID and the KEGG pathway terms are listed above.
Asterisks denote pathways that have been previously known to be modulated
by KSHV.
bPathways involved in cell migration.
cThe number of predicted microRNA target genes involved in each pathway.
dP value. In addition to the predicted targets of the KSHV oncomirs, also shown
are predicted targets of WNV-induced microRNAs, demonstrating the
differences in pathways affected.
eNSCLC, non-small cell lung cancer.
fAML, acute myeloid leukemia.
doi:10.1371/journal.ppat.1003484.t001
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relative expression levels were significantly elevated in mouse models
of KS (p#461025, Figure 5D). To confirm these results, we
performed Caliper gel electrophoresis analysis on the qPCR
products, which confirmed that these miRNAs were overexpressed
in exosomes from our transgenic and TIVE xenograft mouse models
(Figure S15). Taken together, these data reveal that members of the
miR-17-92 cluster are exclusively incorporated into exosomes and
may exhibit diagnostic potential and contribute to tumor develop-
ment and pathogenesis of malignancies such as KS.
Profiling of miRNAs from KS case studies and comparison
to TIVE xenograft mouse models
We profiled the circulating miRNAs in a second, independent
pair of KS patients (n = 2) and compared them to TIVE xenograft
mice along with the appropriate controls (Figure S16). One of the
KS patients profiled had an unusually high KSHV load, multiple
internal lesions and cytokine dysregulation [72]. Unsupervised
clustering analysis confirmed that the TIVE L1 xenograft mice had
a distinct circulating miRNA profile from control mice, but also
revealed that this mouse model shared similarities to the human
miRNome detected in pleural fluid (Figure S16). Like the xenograft
mice, the two KS case study patients expressed distinct circulating
miRNA signatures when compared with control human plasma
(Figure S16). The KS patient with more advanced disease (DG1,
cytokine dysregulation and high KSHV load) displayed a miRNA
profile more similar to TIVE xenograft exosomes. These indepen-
dent biological replicates and multiple clinical cases share a
common, robust signature (Figure S16, Figure 4E,F).
GO pathway analysis of oncomir targets
To gauge the importance of the KS exosome signatures, we
analyzed the oncogenic miRNAs upregulated in tumor-derived
Figure 5. Analysis of oncomiRs and exosomal miRNA subsets. Oncomirs belonging to the miR-17-92 cluster were analyzed for expression. (A)
Box plot showing the distribution of expression scores for ,150 miRNAs associated with cancer for KS biopsies, exosomes in KS patients, exosomes in
normal human plasma and RNase-treated, exosome-depleted supernatant from control plasma. Individual circles represent individual miRNAs and
their respective expression levels in the samples. Blue circles represent members of the oncogenic miR-17-92 cluster while other oncogenic miRNAs
are denoted by red circles. Box plots of relative expression levels of the miR-17-92 and 106b-25 clusters in control and tumor samples are shown in
human (B) and mouse (C) exosome samples. (D) A subset of miRNAs showed exclusive expression in mouse exosomes and not in plasma exosomal
supernatants (free miRNAs). Expression levels in transgenic and xenograft mouse exosomes are also higher than control exosomes for these miRNAs.
Sample abbreviations: exo, KS exosomes; neg, control exosomes; tumor, tumor biopsies; mock, control human or mouse plasma/serum, plasma, KS
patient plasma; pleural, pleural fluid; tg, KSHV latency locus transgenic mice; tum, xenograft tumor mice; cEXO, control exosomes; cSN, control
supernatant; tExo, tumor exosomes; tSN, tumor supernatant fraction.
doi:10.1371/journal.ppat.1003484.g005
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Figure 6. hTERT-HUVEC cell migration is enhanced upon treatment of cells with patient-derived exosomes. (A) hTERT-immortalized
HUVECs were seeded at 80% confluence in a 24-well plate and allowed to equilibrate overnight. Cells were then treated with patient pleural fluid-
derived exosomes for 24 hours prior to beginning the scratch assay. (B) Scratch assay performed with annexin blocking of exosomes. Scratch assay
images are shown at 0 h, 8 h and 16 h post-scratch at 1006magnification. CHP – control human plasma; PF Exo – pleural fluid exosomes; PF Sup –
exosome-depleted pleural fluid supernatant; IL-6 – interleukin 6. (C) Box plots of scratch assay data. Cells treated with exosomes only are shown in
red with the horizontal bar representing the mean of experiments for each group. Data for annexin blocking of exosomes is shown in blue. The
closure index represents the amount of closure detected at 8 hours post-scratch for samples as compared to mock. (D) Dunnett confidence interval
(CI) comparing each treatment to control human exosomes. Black circles represent the 95% CI for each sample, with parentheses denoting the range
observed. Dotted grey line represents CHP compared to CHP as a baseline comparison. (E) Migration assay using the xCelligence system. hTERT-
HUVECs were treated with exosomes for 24 hours and serum-starved for 6 hours. 30,000 cells were plated per well of an xCelligence CIM-Plate 16
(upper chamber) and FBS was used as a chemoattractant (lower chamber). Reads were taken every 2 minutes continuously for 24 hours. Data is
shown as Cell Index and increased cell index reflects increased migration to the lower chamber. (F) Supernatants from the scratch assay (A, B) were
assessed for levels of IL-6 (pg/ml) by ELISA. Box plots show replicates for supernatants of hTERT-HUVECs treated with pleural fluid-derived exosomes
before and after annexin blocking.
doi:10.1371/journal.ppat.1003484.g006
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exosomes using Gene Ontology pathway analysis and found that
many of the miRNAs targeted pathways previously shown to be
central to KSHV pathogenesis (Table 1; asterisks). PI3K/Akt
signaling is central to ‘‘Pathways in Cancer’’, which had the
highest correlation to upregulated miRNAs. It is known to be
dysregulated following KSHV infection [73,74,75]. Many of the
other pathways listed in Table 1 contribute to both the KEGG
Pathways in Cancer and the Pancreatic Cancer pathway. For
instance, MAPK is important in the control of replication and
KSHV reactivation from latency while KSHV inhibits TGF-beta
signaling through mechanisms including miRNA-targeted silenc-
ing [76,77]. KSHV LANA has been shown to bind GSK3-beta,
leading to an upregulation of beta catenin in KS and PEL through
the regulation of Wnt signaling [78]. TLR signaling has previously
been shown to play a role in both primary infection of monocytes
and reactivation from latency [79,80]. Finally, two of the pathway
hits—focal adhesion and adherens junctions—are known to be
important in viral entry, cytoskeletal remodeling and cell adhesion
during KSHV infection and KS tumorigenesis including in
adjacent KSHV-negative spindle cells within the KS lesion [81].
As control, we also analyzed the GO pathways associated with
the miRNA signature of an unrelated virus (WNV). This
confirmed that the roles of the signaling pathways were unique
to our exosome profiling of KSHV-associated malignancies
(Table 1). We also performed GO pathway analysis using two
additional, independent analysis databases: Panther and Ingenuity
Pathway Analysis (Table S4 and S5). These revealed highly
significant pathways targeted by oncomirs including angiogenesis,
integrin signaling, transformation, migration and invasion (Tables
S4, 5). Previous studies of the oncogenic miR-17-92 cluster have
also revealed roles in similar pathways such as NFkB signaling,
angiogenesis, TLR, MAPK, STAT and TGF-beta signaling
[69,82,83,84,85,86,87,88,89,90,91]. Since many of the GO
analysis pathway hits have been previously functionally validated,
it is likely that some of the exosomal miRNAs found overexpressed
in this study contribute to KSHV signaling. One function that
many of these pathways shared is the involvement in cell
migration, which is important for tumorigenesis and noted in
Table 1. We therefore used cell migration as a bioassay to show
that our exosome-enriched samples yielded intact, functional
exosomes.
Treatment of hTERT-HUVECs with patient-derived
exosomes enhances cell migration
Since cell migration was a shared functional outcome of several
of the gene ontology pathway hits, we sought to test the effect of
KS and PEL-derived exosomes on the migration of endothelial
cells. hTERT-immortalized HUVECs [92] were treated with
exosomes isolated using the ExoQuick kit. Exosomes derived from
patient PEL pleural fluid were added to cells for 24 hours and the
wound healing scratch assay was performed to test the migration
capability of these cells. Figure 6A demonstrates that hTERT-
HUVECs treated with patient-derived exosomes displayed
enhanced cell migration by 8 hours post-initiation of the scratch
assay. Cells treated with exosomes derived from control human
plasma (CHP) showed delayed migration compared with cells
receiving the exosomes derived from pleural fluid (Figure 6A). This
confirms that this effect was not due to ExoQuick itself, since
control exosomes isolated using this protocol did not increase
migration. Since we also detected KSHV DNA in the supernatant
fraction of pleural fluid and the presence of virions can also affect
migration, we analyzed the migration capability of cells treated
with exosome-depleted supernatant (PF sup). hTERT-HUVECs
exposed to PF supernatant also displayed enhanced migration
compared to control exosomes but cells treated with pleural fluid-
derived exosomes still migrated more rapidly. As a positive
control, we also treated hTERT-HUVECs with IL-6, which
resulted in increased migration similar to that observed with the
pleural fluid supernatant fraction (IL-6 versus PF sup). Of note,
exosomes are known to carry proteins as well as miRNAs [44]. At
this point, we cannot assign this exosome phenotype to either
moiety. The data also suggests that while cytokines and virus
present in the supernatant can affect cell migration, patient-
derived exosomes further accelerate this process.
Exosomes isolated from cell culture models and patients have
been shown to express phosphatidylserine (PS) on their surface
[39,93]. Since Annexin V can bind PS on the surface, annexin
blocking of exosomes has been previously used as a means of
inhibiting exosome fusion and transfer of exosomal contents
[44,45,93]. Therefore, we also performed the scratch assay in the
presence of annexin blocking (Figure 6B). Exosomes and
supernatants were incubated with Annexin prior to initiation of
the scratch assay. Annexin blocking did not seem to affect the
migration of hTERT-HUVECs treated with control (CHP)
exosomes. However, the enhanced migration potential of cells
treated with pleural fluid-derived exosomes was reversed with
annexin blocking, demonstrating that this phenotype is due to
exosomal transfer. Cells treated with exosome-depleted superna-
tants from pleural fluid were not affected by annexin blocking.
Similarly, IL-6 enhanced cell migration regardless of annexin
blocking. Therefore, any virus or cytokines present in this
supernatant enhanced migration via a different mechanism
independent of exosomes.
Figure 6C provides a boxplot representation of the scratch assay
data. This confirms that cells treated with pleural fluid-derived
exosomes exhibit increased migration, which is reversed by
treatment with annexin. This is also observed following treatment
of cells with exosomes derived from the PEL cell line BCBL1. We
formally tested the individual contributions of each factor to the
increased migration phenotype using a Dunnett confidence
interval test which evaluates the significance of different treatments
compared to a common control and adjusts for potential bias due
to multiple comparisons being performed (Figure 6D). As
represented by the black circles (with brackets representing the
95% confidence interval (CI)), treatment with IL-6 or exosomes
from either pleural fluid or PEL cells independently led to
significantly increased closure of the wound compared to exosomes
isolated from KSHV-negative control human plasma (CHP). By
contrast exosome-free, mock treated cells behaved similarly to cells
treated with exosomes from KSHV-negative CHP.
All scratch assays were performed in triplicate for three
independent biological replicates over a span of two weeks. In
each biological replicate, we observed the same phenotype. Table 2
shows the linear, multivariate analysis of the data, which measures
the difference between two experimental conditions after adjusting
for all other factors. Exosomes derived from pleural fluid of a PEL
patient (p#10211) or from the BCBL1 PEL cell line (p#1027)
significantly enhanced migration of hTERT-HUVECs at 8 hours
post-infection compared to CHP (Table 2b–d). When comparing
the supernatant and exosome fractions of pleural fluid and PEL
cell supernatants, exosomes were more potent (p#0.031), but we
still observed a significant effect on HUVEC migration for the
supernatant (Table 2j). This is not entirely unexpected, since
supernatants from PEL patients and PEL cells have large amounts
of soluble IL-6, IL-10 and VEGF [49]. Still exosomes indepen-
dently confer an enhanced migration phenotype to hTERT-
HUVECs. Annexin blocking of exosome fusion supports this
(p#1027) and resulted in reversal of the enhanced migration effect
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of PEL-derived exosomes (Table 2k, columns b–d). This demon-
strates that our purified exosomes have biological activity, and
second that the KS and PEL patient-derived exosomes confer a
phenotype of enhanced migration to endothelial cells, which is
likely to contribute to KS-associated angiogenesis.
We next analyzed migration of hTERT-HUVECs treated with
exosomes using the xCelligence system, which allows for highly
accurate, quantitative measurements of cell migration in real-time.
The xCelligence Cell Invasion and Migration (CIM) Plate 16
consists of an upper and lower chamber separated by a
microporous membrane coated with gold microelectrode sensors
on the bottom side. As cells migrate toward the chemoattractant in
the bottom chamber, the impedance signal increases and results in
a corresponding increase in Cell Index (proprietary readout,
Roche application note). hTERT-HUVECs were treated with
patient-, cell line- or mouse model-derived exosomes. Cells were
then serum starved and plated into the upper chamber of the CIM
Plate. Migration towards the chemoattractant FBS was continu-
ously monitored every two minutes for a period of 24 hours.
Figure 6E shows that hTERT-HUVECs treated with KSHV-
associated exosomes exhibited increased migration compared with
cells treated with exosomes from control human plasma (red). This
assay independently demonstrates that exosomes from patient PEL
fluid, the BCBL1 PEL cell line, and a xenograft mouse model of
KS confer an enhanced migration phenotype to hTERT-HUVEC
cells.
Since IL-6 plays a significant role in KSHV pathogenesis, we
analyzed the levels of IL-6 present in the scratch assay
supernatants by ELISA (Figure 6F). hTERT-HUVECs treated
with patient-derived exosomes secreted high levels of IL-6. IL6
secretion in response to exosome treatment was decreased when
the exosome fraction was incubated with annexin V (p#0.003).
These experiments suggest that efficient exosome transfer drives
enhanced cell migration, possibly through the increased induction
of cytokines such as IL-6. Note, though, that these experiments did
not distinguish between miRNA and protein components of
the exosomes. In sum, the exosomal signature associated with
KSHV-related malignancies could not only be a reservoir of
clinically important diagnostic biomarkers but may also be a novel
mechanism of paracrine signaling that mediates KSHV-associated
pathogenesis and tumorigenesis.
Discussion
Circulating miRNAs, especially those within exosomes, have
emerged as novel biomarkers [31,32,33,94,95]. Their main
advantage is stability and ease of detection as all miRNAs can
be profiled with a common platform. We previously established
and validated such a miRNA profiling platform [54]. Bodily fluids
such as plasma can be obtained using minimally invasive
techniques and lend themselves to repeat sampling, for instance
to follow therapy. In the case of PEL, periodic (in extreme cases
every few days) draining of pleural cavities is medically indicated.
Although the exosomal miRNA profile of malignancies
associated with EBV have been previously reported [44,45], this
is the first study to examine the circulating miRNA profile of
KSHV-associated cancers. This is also one of a few studies to
compare patient tumors to xenograft mouse models [96]. We
extend previous findings on exosomal miRNAs, which were
largely based on cell culture models. KSHV-encoded miRNAs
were detectable in systemically circulating exosomes (Figure 2I and
Figure 3), including in xenograft mouse models of KS. This
suggests that viral miRNAs can have effects far from the site of the
infected cell. Furthermore, viral microRNAs could potentially
serve as highly specific biomarkers of KSHV-associated malig-
nancies, particularly if the lesions are internal and comprised of
mostly latently infected cells. We found similar levels of viral
miRNAs in exosomes derived from latently infected PEL cells
compared to PEL cells undergoing lytic reactivation (Figure 3A).
Most KS tumor cells and most PEL are latently infected and even
if lytic gene expression is observed in a subset of cells, virions are
seldom produced [97,98].
A significant complication of characterizing exosomal miRNAs
in virally associated diseases is that miRNAs may be incorporated
into virions. Previous studies have shown that viral RNAs can be
detected within herpesvirus virions, including KSHV and EBV
[99,100]. Recently, Lin et al. demonstrated the presence of viral,
as well as cellular miRNAs in purified KSHV virions [64].
Exosomes are difficult to physically separate from virions due to
their similar sedimentation velocities, buoyant densities, biogenesis
and heterogeneous nature of exosomes [44,46]. Others have
circumvented this issue using cell culture models that are incapable
of virus production, such as HCV subgenomic replicon (SGR) cells
[46]. Analogous to this model, we employed several latent models
of KSHV infection, including the latently infected TIVE xenograft
mice, the latency locus transgenic mice and the BCBL1 latent PEL
cell line [48,50]. We believe that the majority of miRNAs we
detect here are exosomal, rather than virion-associated. To
support this interpretation, we offer three lines of evidence.
First, we were able to detect all viral miRNAs in latent BCBL1
exosomes and filtering samples led to decreased viral load but did
not significantly affect levels of KSHV miRNAs (Figure 3, Figure
S7). We detected similar amounts of KSHV miRNAs in exosomes
isolated from latent PEL supernatant as in exosomes from
supernatant of induced PEL (Figure 3). In the same samples, we
observed a greater than 10-fold increase in viral DNA. This
suggests that KSHV miRNAs are released into exosomes from
latently infected PEL, analogous to exosomal EBV miRNAs which
are released from latently infected cells [44,96]. Note, that we are
able to detect KSHV miRNAs in exosomes from 250 ml of latently
infected cell supernatant, whereas at least 500 mls were previously
Table 2. Linear, multivariate analysis of scratch assaysa.
Estimateb SEMc p-valued
(Intercept)e 0.31 0.23 n.s.f
Experimentsg 0.03 0.022 n.s.
CHPh vs. IL6i 1.2 0.22 1.7610207
vs. mock 0.0 0.25 n.s.
vs. PEL cell (BCBL1) 1.1 0.20 4.0610207
vs. PEL patient (PF) 1.3 0.18 5.4610211
SNj vs. Exosome 20.31 0.14 0.031
Mock vs. AnnexinVk 20.75 0.14 3.3610207
aTotal number of assays n = 94.
bEstimates relative effect of variable on fraction of closed area of the scratch
after 8 hours relative to mock treatment. A negative coefficient indicates
inhibition relative to control.
cSEM, standard error of the mean.
dUnadjusted p-value of F test for significance (p#0.05 is considered significant.
eIntercept term of the linear model.
fn.s., not statistically significant.
gTotal number of independent experiments n = 9.
hCHP, control human plasma.
iHuman IL6.
jSN, supernatant fraction after exo quick kit.
kPresence of Annexin V, which prevents exosome fusion.
doi:10.1371/journal.ppat.1003484.t002
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used to enrich for virion-associated miRNAs [64]. We could also
detect KSHV miRNAs in the bloodstream of mice, which carry
KSHV latently-infected TIVE-E1/L1 xenografts. These cells do
not generate infectious virions [48] and (R. Renne, personal
communication).
Second, we were able to isolate exosomes by CD63-mediated
affinity purification (Figure 3). Herpesvirus virions and exosomes
co-purify in almost all centrifugation schemas designed to enrich
for exosomal fractions (i.e. differential ultracentrifugation, sucrose
gradients, ExoQuick solution). By contrast, anti-CD63 Dynabeads
positively select exosomes which carry CD63 as one of their
surface markers [57,101] while CD63(2) virions are eliminated.
This resulted in an enrichment of KSHV miRNAs and
concomitant depletion of viral DNA (Figure 3), demonstrating
that indeed viral miRNAs are present in exosomes. We were also
unable to detect any contaminating virions in our samples
enriched for exosomes by electron microscopy and structural viral
proteins were absent in our exosome-enriched samples (Figure 2A
and Figure S8).
Thirdly, KSHV miRNAs could be detected in exosomes
isolated from the serum of our xenograft mouse model. These
xenograft mice harbor latently infected cells, which do not
generate infectious virus. This suggests that viral miRNAs are
constantly released and circulate systemically in exosomes in mice
(and patients) who harbor KSHV latently infected cells. Taken
together, these data suggest that KSHV latently infected cells can
release viral miRNAs and further demonstrates that exosomes are
the source of these circulating miRNAs.
Human oncogenic miRNAs were easily detected in tumor-
derived exosomes isolated from patient plasma and pleural fluid
(Figure 4). Further analysis confirmed increased levels of the well-
studied miR-17-92 cluster miRNAs. Our data also show poten-
tially important similarities and differences in the miRNA profile
from AIDS patients with KS compared to patients with other non-
viral AIDS-associated malignancies (Figure 4F). This subset of
exosomal miRNAs could reflect differences between the varying
progression of different malignancies in AIDS patients or
similarities among AIDS-associated cancers and merits further
study. Exosomal miRNAs are readily detected in pleural fluid
samples, representing an alternate sample source with potentially
higher correlation to disease state for patients with malignant
effusions. Since pleural fluid is more proximal to the tumor site
than plasma, which circulates throughout the body, we reason that
the circulating miRNome from malignant effusions may be more
reflective of the tumor itself. However, further studies comparing
the miRNA signatures of pleural fluid-derived exosomes from PEL
and other non-KSHV-associated malignancies such as lung cancer
are necessary to reveal diagnostic biomarkers unique to PEL.
We also demonstrated that human and viral miRNAs are
present in circulating exosomes in xenografted mice (Figures 2,4).
We used the TIVE L1 [48] xenograft model, which has been
shown to be predictive of anti-KS therapies [98,102]. The KSHV
miRNAs that we consistently detected in these mouse models
could only stem from the human graft. Due to the high
conservation of cellular miRNAs within the oncogenic clusters,
the cross-species detection of miRNAs using the human assays
makes it difficult to distinguish miRNAs of human versus mouse
origin in these models (Table S3, ABI product information,
miRBase). In some cases, the mature miRNAs share 100%
sequence homology across the entire length, not just the seed
region (miRBase, [103]) and in many cases the targets have co-
evolved as well [69]. We observed greater levels of miRNAs in the
mouse exosomes compared to human exosomes, which may be
due to the fixed 250 ml sample size with respect to the overall
amount of blood circulating within a human (approximately 5 L)
or mouse (approximately 0.0015 L).
Specific host miRNA markers of tumorigenesis also emerged in
our mouse models. We showed previously that host miRNAs are
distinct for different stages of KS tumor progression [6].
Therefore, tumorigenic miRNAs combined with viral miRNAs
would offer a very specific biomarker signature and may also
identify biomarkers for other related cancers. Therefore, we
analyzed expression of the oncogenic miR-17-92 and 106b/25
clusters and found that they were significantly enriched in
exosomes from TIVE tumor-bearing mice compared with controls
(Figure 5). Several of the oncogenic miRNAs expressed in
exosomes were previously found at highly expressed levels in the
TIVE cell line independently (R. Renne, personal communica-
tion). The mir-17-92 cluster was previously shown to be
upregulated in KS tumor biopsies [3,4]. This is the first
demonstration that the miR-17-92 cluster miRNAs are incorpo-
rated into exosomes from KSHV-associated malignancies. These
oncogenic miRNAs have also been detected in exosomes derived
from leukemia cells and those derived from breast milk [56,104],
suggesting that their function is at least in part to mediate
paracrine phenotypes. Viral and cellular miRNAs originating from
the tumor enter the mouse circulatory system and are readily
detected in serum. Since our mouse model exosome signatures
recapitulate the clinical KS signatures, this supports the validity of
xenograft mice as a reliable model system for KS.
We also observed a subset of miRNAs that were highly induced
in exosomes and were virtually undetectable in the free, circulating
miRNA fraction (Figure 5D). The miRNAs detected exclusively in
the exosome fractions are either known to be oncogenic or shown
to be upregulated by KSHV infection [105,106]. This suggests
that certain miRNAs are preferentially incorporated into exo-
somes and that many proliferative and tumor-associated miRNAs
fall into this class. Recently, Palma et al [107] found that
selectively exported miRNAs from malignantly transformed cells
may be incorporated into customized exosomal particles distinct
from the microvesicles that originate from untransformed cells. It
is conceivable that these have different systemic stability and thus
become enriched in a blood sample. This may be the case with
KSHV-induced miRNAs as well since we found miRNAs
originating from our transgene model also to be enriched in this
fraction.
Exosomes serve as a means of intercellular communication with
surrounding cells and the contents of exosomes can be shared
between cells through the mechanism of exosomal transfer
[44,45]. Exosomes can deliver functional miRNAs to recipient
cells and consequently downregulate expression of target genes
[44,45,108]. Leukemia cell-derived exosomes have recently been
shown to affect endothelial cell function through microRNA
transfer [56]. Moreover, tumor-derived microRNAs were recently
reported to play a functional role through binding to Toll-like
receptors, thereby inducing an inflammatory response and
influencing tumor growth and metastasis [109]. This in vivo
relevance was further demonstrated by inhibiting tumor-secreted
miRNAs, which altered tumor formation in mice [109]. Dendritic
cell-derived exosomes can be used to prime the immune response
as cancer immunotherapy to suppress tumor burden
[110,111,112]. Exosomes have also been recently tested in clinical
trials to reduce tumor size [110,111,112,113]. Collectively, these
studies further demonstrate the in vivo relevance of exosomes and
their potential as mediators of disease phenotypes.
In this study, we find stable, systemic KSHV miRNAs and
oncomiRs. GO pathway analysis of predicted targets of the
oncogenic miRNAs expressed in exosomes revealed a variety of
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pathways targeted by KSHV during pathogenesis (Table 1). Since
several of these pathways shared a role in cell migration, we
further tested the effects of patient-derived exosomes on migration
of hTERT-HUVECs. Treatment of cells with exosomes from
pleural fluid led to earlier, enhanced migration of endothelial cells,
giving these patient-derived exosomes a functional biological role
(Figure 6). Therefore, it is possible that miRNAs specifically
expressed within exosomes play a role in disease progression and




De-identified human plasma samples were obtained from
healthy controls, patients enrolled in the UNC AIDS Malignancy
Trial IRB#09-1201 (diagnosed with KS or other, non-KS
malignancies) and patients with Kaposi’s sarcoma. Primary pleural
effusion fluid from three patients was also obtained. For mouse
controls, pooled plasma from C57/BL6 mice was obtained from
Innovative Research (Novi, Michigan). Blood was collected from
C57/BL6 control mice and serum was isolated using a serum-gel
tube (Sarstedt). Blood sera were also purified from KSHV latency
locus (801) transgenic mice [50] and Balb/c mice injected with
TIVE, latently infected KSHV+ endothelial cells [48]. Purified
serum was collected for each group. Samples from each group
were pooled as shown in Table S1 to control for individual genetic
variation among sample groups and to increase the material
available for exosome isolation. Exosome isolations for each
sample group were performed in duplicate.
Ethics statement
The mice were held in UNC animal facilities. Veterinary care
was provided by the University veterinarians and support animal
care staff. The animal facility is an American Association of
Accreditation of Laboratory Animal Care (AAALAC) accredited
facility. The mice were maintained according to AAALAC
guidelines and approved by institutional animal care and use
committee (IACUC) under protocol #10-247/‘‘KSHV latency
mice’’. The UNC Chapel Hill animal welfare assurance number
is: A-3410-01.
Isolation of exosomes and free, circulating miRNAs using
Exoquick
Human plasma, pleural fluid, mouse plasma or serum was
centrifuged at 3006g for 10 minutes to pellet any cells. 250 ml of
supernatant was transferred to a fresh tube and incubated with
63 ml Exoquick precipitation solution as per the manufacturers’
instructions (System Biosciences, Mountain View, California).
After incubation for 16 hours at 4uC, contents of each tube were
centrifuged for 30 minutes at 1,5006g to pellet exosomes. The
supernatant containing free, circulating miRNAs was transferred
to a fresh tube and the exosomal pellet was resuspended in 100 ml
of nuclease-free, PCR-grade water (Life Technologies, Carlsbad,
California). Other studies also have validated the Exoquick
protocol and have not detected any significant differences in
exosome populations compared with ultracentrifugation methods
[56].
Isolation of exosomes by ultracentrifugation
Patient pleural fluid and tissue culture supernatants (35 mls)
were centrifuged for 30 minutes at 2,0006g to pellet cells. The
supernatant was transferred to a fresh tube and centrifuged at
12,0006g for 30 minutes at 4uC. Filtering was performed after
clearance of cellular debris and prior to ultracentrifugation where
noted. Supernatants were transferred to ultracentrifuge tubes and
spun in a SW32Ti swinging bucket rotor for 70 minutes at
110,0006g. The supernatant was discarded and the pellet was
resuspended in 35 mls of sterile PBS and passed through a 0.2-
micron filter. Exosomes were centrifuged at 110,0006g for an
additional 70 minutes to wash. The supernatant was again
discarded and the pellet was resuspended in 1 ml of sterile PBS.
Samples were transferred to 1.5 ml ultracentrifuge tubes and
concentrated by ultracentrifugation at 110,0006g for 70 minutes
using a TLA-100.3 rotor. The resulting pellet was resuspended in
a small volume and used for subsequent experiments.
Exosome enrichment using CD63+ Dynabeads
Samples (35 ml starting material) were ultracentrifuged as
previously described to obtain exosome-enriched samples
(,500 ml). These samples were further enriched for CD63+
exosomes using the CD63+ Dynabead exosome isolation kit
according to manufacturer’s instructions (Invitrogen, Life Tech-
nologies #10606D). Briefly, 500 ml of sample was incubated with
100 ml CD63+ Dynabeads overnight at 4uC. Exosomes were
positively selected using a Dynabeads magnet and samples were
washed to eliminate non-specific binding. Bead-bound exosomes
were resuspended in 300 ml PCR-grade water and approximately
100 ml was used as input for further RNA, DNA and protein
analysis by Western blot and qPCR (Figure 3). Prior to DNA
isolation using the Magnapure automated system (Roche), beads
were treated with Proteinase K (200 mg/ml) for 2 hours at 55uC to
dissociate beads and exosomes.
Filtering of samples for exosome enrichment
To obtain filtered samples, cell supernatants or patient fluids
were first cleared of cellular debris. The resulting supernatant was
passed through either a (1) Nalgene 250 ml Rapid-flow filter unit,
0.2 mm CN membrane, 50 mm diameter (Thermo Scientific,
#126-0020) for ultracentrifugation and Dynabead methods or (2)
Whatman Puradisc 25AS 0.2 mm polyethersulfone membrane
filter (#6780-2502) for the ExoQuick methods. The flow-through
was then used as input for downstream exosome enrichment
protocols (ExoQuick, ultracentrifugation and CD63+ Dynabeads).
Flow-through did not seem to affect exosome yield or loss of
exosomal markers (Figures 2, Figure S6 and data not shown).
Filtration of samples resulted in a decrease in KSHV load as
determined by qPCR for LANA DNA (Figure 3).
RNase treatment
Select samples were treated with RNase prior to exosome
isolation. RNase treatment was performed as described previously
[34]. Briefly, samples were incubated with RNase (Roche –
product # 11119915001, includes both RNase A and T) at 37uC
for 30 minutes to destroy any freely circulating RNAs (Figure S4).
Exosomes were then isolated using the ExoQuick precipitation
solution.
Electron microscopy
Aliquots of purified exosome samples were absorbed directly
onto glow-charged thin carbon foils on 400-mesh copper grids
without fixation and stained with 2% (w/v) uranyl acetate in
water. The grids were examined in an FEI Tecnai 12 (Hillsboro,
OR) electron microscope at 80 kV. Images were captured on a
Gatan Orius CCD Camera (Gatan, Pleasanton, CA) using Digital
Micrograph software. Images for publication were arranged and
contrast optimized using Adobe Photoshop CS4.
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RNA isolations and spike-in control
The supernatant and exosome fractions from each pooled group
were used in full as input for RNA isolations. Total RNA was
isolated using TRI reagent (Molecular Research Center, Cincin-
nati, Ohio) followed by a phenol/chloroform extraction and
ethanol precipitation of RNA as previously described [3,4,6]. Prior
to RNA isolation, 25 fmol of C. elegans cel-mir-39 RNA was added
to each sample as a spike-in control [33,35]. Total RNA was
resuspended in nuclease-free, PCR-grade water and the RNA
concentration was determined using the NanoDrop spectropho-
tometer (Thermo Scientific, Waltham, Massachusetts).
Western blot analysis
Exosomes were isolated using the Exoquick kit as described
above. Both exosomal fractions and supernatants were lysed in
100 ml NP40 lysis buffer (50 mM Tris, 150 mM NaCl, 1% NP-40
with 50 mM NaF, 1 mM sodium vanadate, 30 mM beta-
glycerophosphate, 1 mM PMSF and protease inhibitor cocktail
(Sigma, St. Louis, Missouri). Lysates (10 ml) were run on a 10%
SDS-PAGE gel, transferred to a nitrocellulose membrane
(Hybond, GE Healthcare, Pittsburgh, Pennsylvania) and blocked
in 5% dry milk in Tris-buffered saline with 0.1% Tween 20
overnight at 4uC. CD9 was detected using the CD9 EXOAB
antibody kit as per the manufacturer’s instructions (System
Biosciences, Mountain View, California). Anti-flotillin-2 (BD
#610383) was used at 1:5000 and anti-beta actin (Sigma
#A2228), anti-Hsp90 alpha (Assay Designs #SPS-771) and anti-
Hsp90 beta (Assay Designs #SPA-842) were used at 1:2000.
Secondary HRP antibodies (Vector Labs Cat# PI-1000 – rabbit,
Cat#PI-2000 – mouse, Burlingame, California) were used at
1:10,000 and blots were developed using Pierce ECL Western
blotting substrate (Pierce, Rockford, Illinois).
Taqman profiling of cellular and viral miRNAs
Approximately 1 mg of total RNA in 75 ml PCR-grade water
was DNase-treated using the Turbo-DNase kit (Life Technologies,
Carlsbad, California). The RNA was run on an Agilent RNA
Nano 6000 chip to assess RNA quality and the presence of small
RNA populations. Next, samples (200 ng) were used as input for
cDNA synthesis using the Megaplex RT kit version 3.0, Human
Pools A and B (Life Technologies, Carlsbad, California). Following
cDNA synthesis, samples were further amplified using the
Megaplex PreAmp kit version 3.0, Human Pools A and B (Life
Technologies, Carlsbad, California). The PreAmp product was
diluted 5-fold and the amplified cDNA samples were used as
previously described [54] using a library of 754 Taqman cellular
miRNA primers (Life Technologies, Carlsbad, California) and a
robotic pipetting system for automated plate setup [54] (Tecan,
Männedorf, Switzerland). qPCR reactions were run on a Light-
cycler 480 (Roche, Indianapolis, Indiana). Automated plate setup
and replicates correlated well, with little standard deviation
between replicate CTs and no significant quadrant errors (Figure
S17, average standard deviation among 4 replicates = 0.35 CT).
Reactions were also performed to detect levels of the spike-in
control cel-mir-39 and the KSHV miRNAs using individual
Taqman RT and qPCR miRNA assays (data not shown). PCR
products of KSHV miR-K2 were run on an HTDNA 1K chip on
the Caliper LabChip GX (Caliper Life Sciences, Hopkinton,
Massachusetts) to confirm the results via gel electrophoresis.
Analysis of qPCR-based miRNA profiling data
In-depth statistical analysis of technical replicates was per-
formed in R and revealed little variation in CTs below 45. CT
variation among the same sample in each of 4 quadrants was also
assessed and no significant deviation was observed (Figure S17).
Cycle threshold (CT) values for each sample were averaged across
two technical replicates (one replicate from each exosome
isolation) and those with a CT greater than 45 were excluded
and recorded as negative. The remaining data were assigned
expression scores based on a specific range of CT values. The CT
range of expression was 20–45, with CT = 20 as the highest
expression score (expression score = 3) and CT = 45+ yielding the
lowest score of 0. Expression scores were assigned in increments of
0.5, with one expression class including a range of 4 CTs.
Therefore, any significant difference reported was confirmed as a
difference greater than 4 CTs or approximately 16-fold. The
expression scores were then subjected to unsupervised classical
clustering with Pearson coefficient using Array MinerTM (Optimal
Design, Brussels, Belgium). PCA three-dimensional clustering
figures and heatmaps of miRNA expression are shown.
KSHV viral load assay
Exosomes were isolated using the Exoquick kit as described
above (System Biosciences, Mountain View, California). Exosome
pellets and supernatants containing free, circulating miRNAs and
proteins were resuspended in 200 ml PCR-grade water. Exosome-
enriched samples were then treated with DNase for 30 minutes at
37uC according to manufacturer’s instructions for the Turbo
DNA-free kit (Ambion, Life Technologies). DNase-treated samples
were then adjusted to 500 ml volume and used as input for DNA
extraction on the Magnapure (Roche, Indianapolis, Indiana) using
the large volume kit and program settings for total nucleic acid
from plasma samples. DNA was eluted in 100 ml total volume.
Extracted DNA (5 ml) from each sample was used to determine the
presence of KSHV using primers: F primer 59-GGAAGAGCC-
CATAATCTTGC-39; R primer 59- GCCTCATACGAACTC-
GAGGT-39. Ten-fold dilutions of a KSHV oligonucleotide target
with the following sequence were used to generate a standard
curve: 59-GGAAGAGCCCATAATCTTGCACGACTCA-
GACCTGGAGTTCGTATGAGGC-39. PCR products were
then loaded on an HTDNA 1K chip on the Caliper LabChip
GX (Caliper Life Sciences, Hopkinton, Massachusetts) to confirm
the presence of KSHV DNA.
GO pathway analysis
Oncomirs that were upregulated in the KSHV-associated
sample groups were input into the microRNA target prediction
database (MetA MicroRNA target Interference (MAMI), http://
mami.med.harvard.edu/). The settings used for target prediction
were highest stringency and included only 39UTR target sites. The
Entrez IDs of the predicted targets were used as input for the GO
pathway database DAVID. The KEGG pathway terms of highest
correlation were determined along with statistical significance (P
value) and the number of predicted targets in each pathway.
Specific pathways involved in migration were determined by
searching peer-reviewed literature that included mechanistic data
for migration and each specific pathway. Pathway analysis was
performed for microRNAs induced in KSHV-associated malig-
nancies from our exosome study and for microRNAs induced by
WNV infection in hTERT-HUVEC cells.
Scratch assay
hTERT-HUVEC cells [92] were seeded at 80% confluence in a
24-well plate and allowed to equilibrate overnight before treating
with exosomes for a period of 24 hours. Annexin blocking was
performed as previously described [44]. Briefly, exosomes or
supernatant were incubated with Annexin V-FITC for 1 hour at
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room temperature prior to adding to cells. Cells were grown in
EGM-2 media with all supplements (Lonza, EGM-2 Bulletkit).
Each well was scratched using a standard 200 ml pipette tip and
the location of the scratch was marked to locate the initial scratch
at subsequent time points. Cells were washed with media to
eliminate floating cells and replaced with fresh media immediately
after the wound initiation. Images were captured at 0 h, 8 h and
16 h after the initial scratch. Images are shown at 1006
magnification and were obtained on a Leica DMIL microscope
using a HI Plan 106/0.25 PHI objective and QImaging camera
(Cooled color, RTV 10 bit) paired with QCapture imaging
software 3.0.
xCelligence migration assay
hTERT-HUVEC cells were treated with exosomes isolated
using the ExoQuick method. After 24 hours of incubating with
exosomes, cells were serum-starved for 6 hours and then lightly
trypsinized for 3 minutes to detach cells. Trypsin was inactivated
with media containing FBS and cells were centrifuged at 300 g for
5 minutes. Cells were washed with PBS and the remaining pellet
was resuspended to a concentration of 300,000 cells/ml in serum-
free EBM-2 media (Lonza). 30,000 cells were plated per well of the
upper chamber of an xCelligence CIM Plate 16 (Acea Bioscienc-
es). Prior to CIM plate assembly, both sides of the membrane were
coated with 20 mg/ml fibronectin. Media containing FBS was
placed in the lower chamber as the chemoattractant. The upper
and lower chambers of the CIM plate were assembled and reads
were taken every 2 minutes for a period of 24 hours using the
RTCA DP xCelligence instrument (Acea Biosciences).
IL-6 ELISA
Supernatants from the scratch assay (hTERT-HUVECs treated
with exosomes) were analyzed for levels of IL-6 using ELISA
according to manufacturer’s protocol (eBioscience, #88-7066-88).
Briefly, supernatants were collected at 16 hours post-scratch and
were diluted 1:10 for ELISA. A standard curve of IL-6 positive
control was generated and levels of IL-6 (pg/ml) were calculated.
The average of three technical replicates of two independent
experiments was calculated.
Supporting Information
Figure S1 A small number of miRNAs account for the
majority of the miRNA reads in Herpesvirus-associated
lymphoma. (A) microRNA sequencing data of control tonsil,
EBV-negative PEL and EBV-positive PEL. Cellular microRNAs
are shown in blue, EBV microRNAs in red and KSHV
microRNAs in green. Small RNAs were isolated and subjected
to sequencing using Illumina methods and reagents. Raw read
counts for each miRNA were transformed by taking the log of the
square root of the counts. The majority of the microRNA reads
could be attributed to expression of only a few microRNAs.
Comparison of the EBVnegPEL and EBVposPEL to tonsil shows
that a few viral microRNAs dominated the overall microRNA
profile. (B) Quantile-Quantile (QQ) probability plot of the miRNA
sequencing count data. Transformed counts (log of the square root
of counts) were plotted against the standard deviation from the
mean. The dotted line represents the expected data for a normal
distribution. However, the solid gray line demonstrates that the
sequencing count data does not follow normal distribution and
instead several microRNAs (top right) are highly expressed and
others are expressed at levels lower than expected with a normal
distribution (bottom left).
(TIF)
Figure S2 Immunohistochemistry of KS and xenograft
mouse models. Representative hematoxylin and eosin staining
of the xenograft mouse model and KS tissue. The panels highlight
the differences between primary KS and a xenograft mouse model
of PEL, xPEL. The xL1 TIVE model is the most representative of
KS, which is also reflective of our profiling results. Note the
different morphological features of xPEL and xL1.
(TIF)
Figure S3 Exosomal RNA consists of small RNAs but
lacks rRNA. Total RNA samples isolated from BCBL1 PEL cells
or BCBL1-derived exosomes were run on the Agilent to assess
RNA content. Samples were loaded onto an Agilent RNA Nano
6000 chip and shown are the resulting electropheregrams. In the
cellular RNA sample, ribosomal RNA was detected, noted by the
18S and 28S subunit peaks. Cellular RNA also contained small
RNAs, denoted by the small peak on the left. The lower marker
also yielded a peak. The exosome samples only contained small
RNAs and lacked both ribosomal RNA subunits as expected.
(TIF)
Figure S4 RNase treatment efficiently eliminates freely
circulating microRNA. 25 fmol of C. elegans cel-mir-39 was
added to each pleural fluid sample. For use as a spike-in internal
control, cel-mir-39 was added after a 5 minute incubation with
Triazol, prior to addition of chloroform. This is denoted as ‘‘spike-
in’’. The intrinsic RNase activity of pleural fluid was also assessed
by incubating cel-mir-39 with pleural fluid at 37uC for 30 minutes.
Pleural fluid did exhibit some intrinsic RNase activity. To verify
the activity of RNase treatment, cel-mir-39 was added to pleural
fluid and a mix of RNase A/T (Roche) was added at either 10 or
100 U/ml. Samples were incubated at 37uC for 30 minutes
followed by RNA isolation. As a negative control, levels of cel-mir-
39 were assessed in pleural fluid samples without the cel-mir-39
spike-in. Samples were normalized using equal input and values
are shown as dCT of the sample without cel-mir-39. ND, not
detected or below the limit of detection.
(TIF)
Figure S5 ExoQuick purification of exosomes yields EM
images with high background that is not due to cellular
debris. Samples of primary pleural fluid were enriched for
exosomes using the ExoQuick protocol according to manufactur-
er’s recommendations. Negative staining of exosomes was
performed and EM images were taken under the conditions
described. Scalebars are shown for each image. (A) Exosomes
enriched using the standard ExoQuick protocol. (B) Pleural fluid
samples were spun at 10,0006g for 30 minutes to eliminate
cellular debris prior to performing the ExoQuick protocol. (C)
Exosomes were enriched using the ExoQuick protocol and then
overlayed onto a 30% sucrose cushion. The sample was then
centrifuged at 10,0006g for 1 hour and the bottom fraction
containing exosomes was imaged. Note, the particulate matter has
a diameter ,30 nm, i.e. smaller than exosomes or virions.
(TIF)
Figure S6 Exosome populations express exosomal
markers regardless of isolation technique. Exosomes
isolated by ultracentrifugation (UC) or Exoquick (EQ) protocols
were analyzed for purity. (A) The exosomal markers Hsp90 alpha
(A, B), Hsp90 beta (C), flotillin-2 (D) and beta actin (E) were
analyzed by Western blot in human samples isolated by UC and
EQ techniques. All exosome markers were detected in pleural fluid
exosomes isolated by either ultracentrifugation (UC) or Exoquick
(EQ) solution, confirming that both of these protocols yield
populations of purified exosomes. Since these markers are cellular
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proteins that are enriched in exosomes (ExoCarta, www.exocarta.
org), these proteins were also expressed in cell lysates from BCBL1
PEL cells (denoted as ‘‘Cells’’). As expected, the exosomal markers
were absent in the supernatant fraction. Note, only 250 ml of
pleural fluid was used as input for the Exoquick protocol and
,35 mls pleural fluid was used as starting volume for the
ultracentrifugation method. Sample were normalized by equal
input volumes for each technique.
(TIF)
Figure S7 KSHV miRNAs are not significantly affected
by filtering of exosome-enriched samples. Supernatants
from latently infected BCBL1 cells were collected and exosomes
were isolated using the ExoQuick method. Prior to ExoQuick
enrichment, supernatants were passed through a 0.2 micron
Whatman filter to decrease the amount of virus present in the
sample. RNA from BCBL1 cells was used as a positive control for
expression of KSHV miRNAs. PCR-grade water was used as
input for the cDNA reaction for a no template control (NTC).
Total RNA was isolated using Triazol and samples were
normalized to equal amounts of total RNA input. Taqman
microRNA assays (Life Technologies) for 14 KSHV miRNAs were
used to determine levels of expression by qPCR, which are shown
as fold above background for three technical replicates. qPCR
products were diluted 1:10 and run on a Caliper nanofluidics
platform (similar to traditional gel electrophoresis). The KSHV
miRNA products run at ,60 bp with the primers and Taqman
probe annealed. Cells, exosomes and filtered exosomes expressed
KSHV miRNAs to similar levels. A shifted band consisting of the
primer dimers can be seen in the NTC lanes. Abbreviations: Exo,
exosomes; Exo-F, filtered exosomes; NTC, no template control.
(TIF)
Figure S8 The structural protein K8.1 is not detected
within exosome fractions. The BCBL1 PEL cell line was
cultured and cells were reactivated with either 1.25 mM sodium
butyrate (NaB) and 20 ng/ml TPA or 1.25 mM vorinostat. After
48 hours, latent and reactivated BCBL1 cells were collected.
Pleural fluid-derived exosomes (PF exo) were isolated using
ExoQuick and all samples were lysed in NP40 buffer containing
proteinase (Sigma) and phosphatase inhibitors. Samples were
loaded onto a 10% polyacrylamide-SDS gel and then transferred
to a nitrocellulose membrane (Hybond). The membrane was
blocked with 5% dry milk in TBST overnight and then incubated
with primary K8.1 anti-mouse at 1:100 followed by anti-mouse
secondary antibody at 1:5000. Blots were developed using Pierce
ECL substrate kit and Blue Devil autoradiography film and a
representative blot of three independent experiments is shown.
K8.1 was only expressed in reactivated BCBL1 cells and was
absent in both latently infected BCBL1 cells and PF-derived
exosomes.
(TIF)
Figure S9 Latency locus transgenic mice express a
distinct miRNA signature compared to control mice.
Comparative analysis of exosomal miRNA profiles from trans-
genic mice encoding the KSHV latency locus (Tg400, Tg401) and
control mice (Ctrl 61, Ctrl 64). Mouse serum (250 ml) from
individual control and transgenic mice were used as input for the
ExoQuick exosome isolation method. Following RNA isolation,
cDNA was amplified and Taqman miRNA profiles of each sample
were performed as described in the methods section. (A) Density
distribution (red) and histogram (gray) of median CT of n: 384
miRNAs across all samples. (B) Cumulative density plot for the
same data. (C) Waterfall plot of the median CT for each of the
miRNAs in the transgenic mice is shown in red. White lines
indicate median CT for control mouse samples. Yellow lines
indicate 1, 2 and 3 standard deviations of the median CT of the
positive sample, representing the expression percentile under the
assumption of a normal distribution of the data. (D) Heatmap of
CT values for all miRNAs in all samples (blue indicating absence,
white intermediate and brown, highest levels of a given miRNA).
Clustering was based on Ward’s criteria and Manhattan distance
metric.
(TIF)
Figure S10 Profiling of oncomirs in transgenic and
xenograft mouse models. Heatmaps reflective of unsupervised
clustering analysis are shown for oncomirs in mouse samples.
Oncomirs from mouse models are shown as a series of panels (i–
iv). Panel i compares oncogenic miRNA expression between
control mice and individual TIVE xenograft mice. Profiling data
from the transgenic mouse model encoding the KSHV latency
locus is shown in Panel ii with control mice and the average of the
TIVE xenograft data. Panels iii and iv show two separate clusters
of miRNA expression and compare control and transgenic mice to
the primary human PEL pleural fluid cases. Abbreviations of
mouse samples are as follows: CMP – control mouse plasma, CMS
– control mouse serum, TIVE 1–3, individual TIVE xenograft
mice, tg – 801 latency locus mouse model, PF – primary human
PEL pleural fluid, exo – exosomes, sup – exosome-depleted
supernatants. The names of each microRNA in the cluster are
shown to the right of each heatmap. Red denotes high expression,
green denotes low expression and black is basal or intermediate
expression.
(TIF)
Figure S11 Profiling of oncomirs in human patient
samples. Heatmaps reflective of unsupervised clustering analysis
are shown for oncomirs in human samples. Oncomir expression in
human samples is shown as two separate clusters of expression. For
the human oncomiR heatmap, sample lanes from left to right are:
CHP sup pre-exo - control human plasma supernatant pre-
ExoQuick, CHP E – control human plasma exosomes, CHP S –
control human plasma exosome-depleted supernatant, RNase
CHP E – RNase-treated CHP exo, RNase CHP S – RNase-
treated CHP sup, AMT E – AIDS Malignancy, non-KS exo,
AMT S – AIDS Malignancy, non-KS sup, KS E – Kaposi’s
sarcoma exosomes, KS S – Kaposi’s sarcoma exosome-depleted
supernatant, PF E – pleural fluid exosomes, PF S – pleural fluid
exosome-depleted supernatant. The names of each microRNA in
the cluster are shown to the right of each heatmap. Red denotes
high expression, green denotes low expression and black is basal or
intermediate expression.
(TIF)
Figure S12 PF- and CHP-derived exosomal miRNA
profiles respond similarly to RNase treatment. Exosomes
were isolated using the ExoQuick solution and equal volumes
(250 ml) of pleural fluid (PF) or control human plasma (CHP).
Samples were either left alone (2) or treated with 25 U/ml RNase
(Roche) for 30 minutes at 37uC (+). RNA was isolated from
exosome-enriched samples and the miRNA expression profile was
determined by qPCR using Taqman microRNA assays from
human pool A v2.1 (Life Technologies). Heatmap of CT values for
all miRNAs in all samples (blue indicating absence, white
intermediate and brown, highest levels of a given miRNA).
Clustering was based on Ward’s criteria and Manhattan distance
metric. The heatmap shows that the majority of miRNAs
increased in PF-derived exosomes were not affected by RNase
treatment. Similarly, the expression profile of control human
plasma exosomes did not significantly change in response to
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RNase treatment. This demonstrates that different patient samples
have similar responses to RNase treatment and that exosomal
miRNAs are largely RNase-resistant.
(TIF)
Figure S13 Profiling of individual PEL patients reveals
insight into variability of miRNA profiles. Comparative
analysis of exosomal miRNA profiles from individual PEL patient
fluids (pleural fluid patients 1–3) and KS-free control fluids (CHP,
control human plasma). Pleural fluid from individual PEL patients
and control human plasma were used as input for the ExoQuick
exosome isolation method. Following RNA isolation, cDNA was
amplified and Taqman miRNA profiles of each sample were
performed as described in the methods section. (A) Density
distribution (red) and histogram (gray) of median CT of n: 384
miRNAs across all samples. Indicated in orange is the CT = 50
cutoff. (B) Cumulative density plot for the same data. (C) Waterfall
plot of the median CT for each of the miRNAs in the PEL patient
fluids (PF1-3) shown in red. White lines indicate median CT for
KSHV negative samples (CHP a and b). Yellow lines indicate 1, 2
and 3 standard deviations of the median CT of the positive
sample, representing the expression percentile under the assump-
tion of a normal distribution of the data. (D) Heatmap of CT
values for all miRNAs in all samples (blue indicating absence,
white intermediate and brown, highest levels of a given miRNA).
Clustering was based on Ward’s criteria and Manhattan distance
metric. MiRNAs were highly expressed in PF-derived exosomes
compared to control exosomes. A large number of these PEL
signature miRNAs were expressed in all three patients and could
thus be novel biomarkers of PEL. Despite the inherent genetic
variability among patients, we could identify multiple miRNAs
that were expressed at high levels in all three PEL patients
compared to controls.
(TIF)
Figure S14 MiRNA profiling of KS biopsies and PBMCs
from control human plasma. Comparative analysis of
miRNA profiles from KS biopsies and PBMCs from control
human plasma (CHP pellet). Four primary KS biopsies were
pooled to obtain the KS biopsy pool sample. (A) Density
distribution (red) and histogram (gray) of median CT of n: 384
miRNAs across all samples. Indicated in orange is the CT = 45
cutoff. (B) Waterfall plot of the median CT for each of the
miRNAs in the KS biopsy samples shown in red. White lines
indicate median CT for CHP pellet sample. Yellow lines indicate 1
and 2 standard deviations of the median CT of the positive
sample, representing the expression percentile under the assump-
tion of a normal distribution of the data. (D) Heatmap of CT
values for all miRNAs in all samples (blue indicating absence,
white intermediate and brown, highest levels of a given miRNA).
Clustering was based on Ward’s criteria and Manhattan distance
metric. KS biopsies display a unique miRNA profile compared to
CHP cells, with increased levels of several oncogenic miRNAs in
all 4 KS biopsies (also seen in Figure 5).
(TIF)
Figure S15 Caliper gel analysis of oncomirs induced in
tumor mouse models. Gel electrophoresis analysis of qPCR
products of known oncomirs that were upregulated in tumor
mouse models in our profiling study. qPCR products were diluted
1:5 with molecular grade water and run on the Caliper GX
Labchip using the HTDNA 1K chip (Caliper Life Sciences,
Hopkinton, Massachusetts). This chip functions analogous to a
traditional agarose gel and shown is an image of the band
migration. Induction of these microRNAs in tumor mouse models
was confirmed by increased band intensity of the PCR product
compared with control mouse serum (CMS). This confirms the
specificity of the assay and that key oncogenic miRNAs are
enriched in exosomes from our mouse models of KS. Abbrevia-
tions: CMS, control mouse serum, Tg, 801 latency locus
transgenic mouse model, Xeno, SLK xenograft mouse model,
Neg., no template control (PCR-grade water), MW (molecular
weight ladder). The band intensity was measured using Image J gel
analysis (rsbweb.nih.gov/ij/) and is shown in arbitrary units of
band intensity.
(TIF)
Figure S16 Circulating microRNA profiles of TIVE
xenograft model and KS case studies. Comparative analysis
of exosomal miRNA profiles from human (PF, DG1, DG2),
murine xenograft models (TIVE1, TIVE2, TIVE3) and KS-free
control fluids (CHS, human serum and CMS, mouse serum) and
non-template control (NTC). (A) Density distribution (red) and
histogram (gray) of median CT of n: 384 miRNAs across all
samples. Indicated in orange is the CT = 45 cutoff. (B) Cumulative
density plot for the same data. (C) Waterfall plot of the median CT
for each of the miRNAs in the KSHV positive samples (TIVE1,
TIVE2, TIVE3, PF, DG1, DG2) shown in red. White lines
indicate median CT for KSHV negative samples (CMS, CHS,
NTC). Yellow lines indicate 1, 2 and 3 standard deviations of the
median CT of the positive sample, representing 68.3, 94.5 and
97.7 percentile under the assumption of a normal distribution of
the data. (D) Heatmap of CT values for all miRNAs in all samples
(blue indicating absence, white intermediate and brown, highest
levels of a given miRNA). Clustering was based on Ward’s criteria
and Manhattan distance metric. (E–G) Plots comparing the first
three dimensions of the principal component analysis (PCA) using
n = 184 highly changed miRNAs. These were selected based on a
median absolute deviation (m.a.d.) .4 across all samples. These
demonstrate clustering of the control samples and KSHV positive
samples. (H) Histogram of the Eigenvalues of the dimensions of the
PCA analysis. Higher Eigenvalues indicate a greater contribution
of a given distribution to the data variability. (I) Expected false
positive rate on the vertical axis compared to the number of
significant tests on the horizontal axis. This was obtained by
calculating p values of an unpaired, two-sided t-test, allowing for
unequal variance for comparison of the positive samples (TIVE1,
TIVE2, TIVE3, PF) to negative samples (CHS, CMS, NTC) for
each primer followed by adjustment for multiple comparisons
using q-value method. Less than a single false positive miRNA is
expected within the top 20 differentially expressed miRNAs, which
therefore constitute a class signature. (J) Density distribution (red)
and histogram (gray) of unadjusted log10 (p values) from t-test.
The orange line indicates p#0.01. (K) Cumulative density
distribution (red) and histogram (gray) of q values from t-test. (L)
Comparison of log10(q value) on the vertical axis to median CT
for a given miRNA in the KS positive group.
(TIF)
Figure S17 Technical replicates of microRNA data
reveal little variation using an automated liquid-han-
dling system. Technical replicates of microRNA expression
data were obtained using a Tecan Freedom Evo liquid-handling
system. (A) Comparison of the median CTs shows linear
correlation between technical replicates. (B) For each 384-well
plate, 96 primers are run against 4 samples in each of 4 quadrants.
In this test set, the same sample was run in each of 4 quadrants.
Analysis of the microRNA data from each quadrant was
conducted and revealed the absence of any quadrant bias.
Furthermore, it shows tight correlation between technical
replicates for CTs up to ,45. (C) The distribution of the median
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CTs are plotted against the standard deviation of the CT. This
recapitulates that there is little variation in technical replicates at
lower CTs (up to ,40). However, for CTs between 45 and 55,
there can be highly variable deviation from the median. (D) Q-Q
plot showing that the microRNA data of technical replicates
follows a normal distribution, which is represented by the dotted
line.
(TIF)
Table S1 Clinical human and mouse model samples
used in exosome study. Sample groups used for miRNA
profiling are shown along with the number of samples pooled for
each group (N).
(DOCX)
Table S2 List of microRNAs included in the oncomiR
and tumor suppressor array. The Taqman microRNA
primers used in the oncomiR and tumor suppressor array are
listed. These ,150 microRNAs include known oncomiRs and
tumor suppressor microRNAs according to published literature
and references are shown for each microRNA. A subset of these
microRNAs were cross-referenced to the Quantimir cancer array
(System Biosciences) for confirmation of oncomir status. Micro-
RNAs previously found to be altered in KSHV-associated
malignancies are also noted with an ‘‘x’’.
(DOCX)
Table S3 Species cross-reactivity of Taqman microRNA
assays. Product information from Life Technologies, Applied
Biosystems. Recommended controls and 158 of the Taqman
microRNA assays are shown with their mature microRNA
sequence, Taqman assay name and species cross-reactivity for
human, mouse and rat. Many of the assays exhibit substantial
species cross-reactivity due to the conservation of microRNA
sequences.
(PDF)
Table S4 Ingenuity Pathway Analysis of predicted
oncomir targets. Oncomirs used in the microRNA profiling
array and induced in KSHV-associated exosomes were used as
input for Ingenuity Pathway Analysis (www.ingenuity.com/
products/pathways_analysis.html). Predicted targets were ob-
tained using Ingenuity and were narrowed down to include only
experimentally validated targets. These targets were then over-
layed with the functional pathway tool and the top represented
pathways are shown. The number of target genes involved in each
pathway is shown along with the univariate p value as determined
by Ingenuity software. Several pathways are bolded to denote their
importance in tumorigenesis and KSHV pathogenesis. As a
control, we used miRNAs induced by WNV infection of hTERT-
HUVEC cells.
(DOCX)
Table S5 Pathway analysis of predicted targets using
the Panther Database. Predicted targets were obtained
through the Ingenuity program and only included experimentally
validated microRNA targets. The Entrez IDS of predicted targets
were used as input for the Panther database (www.pantherdb.org)
[114]. Pathway analysis was performed and the number of target
genes involved in the top pathways are denoted. WNV-induced
predicted targets were used as a control experiment and revealed
different target pathways. The total number of predicted target
genes for the KS-associated exosomal microRNAs and WNV-
induced microRNAs were 188 and 106, respectively. Differences
between KSHV oncomir targets and WNV-induced targets were
significant as determined by paired T test (p = 1.56E-06).
(DOCX)
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